

chain nodes :

18 19 20 21 22 23 24

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

7-12 9-19 10-18 16-20 17-21 20-22 21-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17

exact/norm bonds :

5-7 6-11 7-8 8-9 9-10 10-11 10-18 16-20 17-21 20-22 21-23

exact bonds :

7-12 9-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

10/256,198

=> d his

(FILE 'HOME' ENTERED AT 15:16:56 ON 20 SEP 2005)

FILE 'REGISTRY' ENTERED AT 15:17:21 ON 20 SEP 2005

L1 STRUCTURE UPLOADED

L2 45 S L1

L3 995 S L1 SSS FUL


FILE 'CAPLUS' ENTERED AT 15:17:51 ON 20 SEP 2005

L4 28 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

10/256,198

ANSWER 1 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:673302 CAPLUS
DOCUMENT NUMBER: 143:172909
TITLE: Preparation of tricyclic benzazepines as squalene
synthase inhibitors used for the treatment of
cardiovascular diseases
INVENTOR(S): Woltering, Elisabeth; Haerter, Michael; Flessner,
Timo; Jeske, Mario; Griebenow, Nils; Suessmeier,
Frank; Bischoff, Hilmar; Raabe, Martin; Buchmueller,
Anja; Kolkhof, Peter; Ellinghaus, Peter; Weber, Olaf
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068472	A1	20050728	WO 2004-EP14871	20041231
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 102004001871	A1	20050901	DE 2004-102004001871	20040114
PRIORITY APPLN. INFO.:			DE 2004-102004001871A	20040114
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = (CH₂)_n; n = 1-3; A = aryl, heteroaryl, etc.; X = O, S, NR₅; R₅ = H, alkyl; Y = N, CR₆; R₆ = H, OH, alkyl; R₁, R₂ = H, halo, CN, etc.; R₃ = alkyl, alkenyl, alkynyl, etc.; R₄ = OR₇, NR₈R₉; R₇ = H, alkyl; R₈, R₉ = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of thioamide II and acetyl hydrazine afforded tricyclic benzazepine III in 49% yield. In squalene synthase inhibition assays, compds. I exhibited IC₅₀ values <10 µM.


IT **860653-00-5P 860653-01-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic benzazepines as squalene synthase inhibitors used for the treatment of cardiovascular diseases)

RN 860653-00-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

10/256,198



RN 860653-01-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

DA ANSWER 2 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:638758 CAPLUS
DOCUMENT NUMBER: 143:139213
TITLE: Method of improving suitability for granulation
INVENTOR(S): Murakawa, Yusuke; Fukuta, Makoto
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065715	A1	20050721	WO 2004-JP19767	20041224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2003-430169 A 20031225

AB Disclosed are granules which comprise a compound having poor wettability and a surfactant, especially ones at least about 35 weight% of which do not pass through a Number 100 screen. Also provided is a process for producing granules containing a compound with poor wettability and having improved suitability for granulation, the process comprising adding a surfactant to the compound before or during granulation especially in such an amount that the weight ratio of the surfactant to the compound is from about 0.001 to about 2.

IT 383652-98-0


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactants for improving granulation of drugs with poor wettability)

RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/256,198



REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:120907 CAPLUS

DOCUMENT NUMBER: 142:219318

TITLE: Preparation of benzoxazepine derivatives as squalene synthase inhibitors

INVENTOR(S): Marui, Shogo; Miki, Takashi; Miura, Shoutarou; Nishimoto, Tomoyuki; Nakada, Yoshihisa

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 239 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012272	A1	20050210	WO 2004-JP11293	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005068138	A2	20050317	JP 2004-222658	20040730
PRIORITY APPLN. INFO.:			JP 2003-285341	A 20030801
OTHER SOURCE(S):			MARPAT 142:219318	
GI				



AB The title compds. I (ring A and ring B each represents an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl optionally substituted by optionally substituted hydroxy; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, O, or S; X3 represents a bond or an optionally substituted divalent hydrocarbon group; and Y represents optionally esterified or amidated carboxy) are prepared A

process for preparing I is disclosed. Thus, (2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]methyl]-1,3-thiazol-5-yl)acetic acid was prepared in a multistep process from 2-(tert-butoxycarbonylamino)acetic acid and potassium monoethyl malonate. Compds. of this invention are said to show IC50 values of $\leq 1 \mu\text{M}$ against squalene synthase. Formulations are given.

IT 839723-04-5P 839723-05-6P 839723-06-7P
839723-07-8P 839723-08-9P 839723-09-0P
839723-10-3P 839723-11-4P 839723-12-5P
839723-13-6P 839723-14-7P 839723-15-8P
839723-16-9P 839723-17-0P 839723-18-1P
839723-19-2P 839723-20-5P 839723-21-6P
839723-22-7P 839723-23-8P 839723-24-9P
839723-25-0P 839723-26-1P 839723-27-2P
839723-28-3P 839723-29-4P 839723-30-7P
839723-31-8P 839723-32-9P 839723-33-0P
839723-34-1P 839723-35-2P 839723-36-3P
839723-37-4P 839723-38-5P 839723-39-6P
839723-40-9P 839723-41-0P 839723-42-1P
839723-43-2P 839723-44-3P 839723-45-4P
839723-46-5P 839723-47-6P 839723-48-7P
839723-49-8P 839723-50-1P 839723-51-2P
839723-52-3P 839723-53-4P 839723-54-5P
839723-55-6P 839723-56-7P 839723-57-8P
839723-58-9P 839723-59-0P 839723-60-3P
839723-61-4P 839723-62-5P 839723-63-6P
839723-64-7P 839723-65-8P 839723-66-9P
839723-67-0P 839723-68-1P 839723-69-2P
839723-70-5P 839723-71-6P 839723-72-7P
839723-73-8P 839723-74-9P 839723-75-0P
839723-76-1P 839723-77-2P 839723-78-3P
839723-79-4P 839723-80-7P 839723-81-8P
839723-82-9P 839723-83-0P 839723-84-1P
839723-85-2P 839723-86-3P 839723-87-4P
839723-88-5P 839723-89-6P 839723-90-9P
839723-91-0P 839723-92-1P 839723-93-2P
839723-94-3P 839723-95-4P 839723-96-5P
839723-97-6P 839723-98-7P 839723-99-8P
839724-00-4P 839724-01-5P 839724-02-6P
839724-03-7P 839724-04-8P 839724-05-9P
839724-06-0P 839724-07-1P 839724-08-2P
839724-09-3P 839724-10-6P 839724-11-7P
839724-12-8P 839724-13-9P 839724-14-0P
839724-15-1P 839724-16-2P 839724-17-3P
839724-18-4P 839724-19-5P 839724-20-8P
839724-21-9P 839724-22-0P 839724-23-1P
839724-24-2P 839724-25-3P 839724-26-4P
839724-27-5P 839724-28-6P 839724-29-7P
839724-30-0P 839724-31-1P 839724-32-2P
839724-33-3P 839724-34-4P 839724-35-5P
839724-36-6P 839724-37-7P 839724-38-8P
839724-39-9P 839724-40-2P 839724-41-3P
839724-42-4P 839724-43-5P 839724-44-6P
839724-45-7P 839724-46-8P 839724-47-9P
839724-48-0P 839724-49-1P 839724-50-4P
839725-25-6P 839725-26-7P 839725-27-8P
839725-28-9P 839725-29-0P 839725-30-3P

839725-31-4P 839725-32-5P 839725-33-6P
 839725-34-7P 839725-35-8P 839725-36-9P
 839725-37-0P 839725-38-1P 839725-39-2P
 839725-40-5P 839725-41-6P 839725-42-7P
 840494-05-5P 840494-06-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839723-04-5 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-05-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/256,198

RN 839723-06-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-07-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-08-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-09-0 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-10-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-11-4 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[[1-(hydroxymethyl)cyclobutyl]methyl]-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-12-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[[1-(hydroxymethyl)cyclobutyl]methyl]-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-13-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-3-yl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-14-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-15-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-ethyl-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-16-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-17-0 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-18-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-19-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-20-5 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-methoxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-21-6 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-22-7 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-23-8 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-24-9 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-25-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-26-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-27-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-28-3 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-29-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-30-7 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, calcium salt (1:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 839723-31-8 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, calcium salt (1:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 839723-32-9 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, calcium salt (1:1) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-33-0 CAPLUS

CN 5-Oxazolebutanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-34-1 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-35-2 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-36-3 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-37-4 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-38-5 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-39-6 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-ethyl-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-40-9 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-41-0 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-42-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-43-2 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-carboxy-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-44-3 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-carboxy-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-45-4 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-carboxy-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-46-5 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-carboxy-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/256,198



RN 839723-47-6 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(2-carboxyphenyl)-, 4-ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-48-7 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(3-carboxyphenyl)-, 4-ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-49-8 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(4-carboxyphenyl)-, 4-ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-50-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(2-carboxyphenyl)-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-51-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(3-carboxyphenyl)-5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-52-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(4-carboxyphenyl)-5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-53-4 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-54-5 CAPLUS

CN 2-Propenoic acid, 3-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-1H-pyrazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-55-6 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-56-7 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-57-8 CAPLUS

CN 1,3,4-Oxadiazole-2-acetic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-58-9 CAPLUS

CN 1,3,4-Thiadiazole-2-acetic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-59-0 CAPLUS

CN 1,3,4-Thiadiazole-2-propanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-60-3 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-61-4 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-62-5 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-63-6 CAPLUS

CN 1,2,4-Oxadiazole-5-acetic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-64-7 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxylic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-65-8 CAPLUS

CN 1H-1,2,4-Triazole-3-acetic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


..Absolute stereochemistry.



RN 839723-66-9 CAPLUS

CN Benzoic acid, 3-[3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-67-0 CAPLUS

CN Benzoic acid, 3-[3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-68-1 CAPLUS

CN Benzoic acid, 4-[3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-69-2 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-70-5 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-ethoxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-71-6 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-72-7 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 5-(carboxymethoxy)-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-73-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-74-9 CAPLUS

CN Benzenepropanoic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-75-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 839723-76-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 839723-77-2 CAPLUS

CN 2-Propenoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-78-3 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-79-4 CAPLUS

CN Benzenepropanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-80-7 CAPLUS

CN Benzenepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-81-8 CAPLUS

CN Benzenebutanoic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-82-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-83-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-84-1 CAPLUS

CN Benzoic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-85-2 CAPLUS

CN Benzoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-86-3 CAPLUS

CN Acetic acid, [4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-87-4 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-88-5 CAPLUS

CN 3-Furancarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-89-6 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-90-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-91-0 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-92-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-93-2 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-94-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-95-4 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-96-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-97-6 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-98-7 CAPLUS

CN 2-Propenoic acid, 3-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-1H-pyrazol-4-yl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-99-8 CAPLUS

CN 1,3,4-Thiadiazole-2-butanoic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-00-4 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-01-5 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-02-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

RN 839724-03-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -(phenylmethylene)-, (α Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-04-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -hydroxy-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-05-9 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β,β-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-06-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-07-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-08-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-09-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-10-6 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-11-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-12-8 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-13-9 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-4-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-14-0 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-15-1 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- β,β -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-16-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-17-3 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-18-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-19-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-20-8 CAPLUS

CN 2-Thiopheneacetic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-21-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-22-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-23-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-24-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-25-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-26-4 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-27-5 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-28-6 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-29-7 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-30-0 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-31-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-32-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-33-3 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-34-4 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-35-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-36-6 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-37-7 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-38-8 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-39-9 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-40-2 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-41-3 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-42-4 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-43-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-methyl-, (βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-44-6 CAPLUS

CN Acetic acid, [[[3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-45-7 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-46-8 CAPLUS

CN Acetic acid, [[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-47-9 CAPLUS

CN Acetic acid, [[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-48-0 CAPLUS

CN Acetic acid, [[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-49-1 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-50-4 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-25-6 CAPLUS

CN Propanoic acid, 2-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-26-7 CAPLUS

CN Butanoic acid, 4-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-27-8 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-28-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-29-0 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-30-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-31-4 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-32-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-33-6 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-34-7 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-35-8 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-36-9 CAPLUS

CN 1,3,4-Oxadiazole-2-butanoic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-37-0 CAPLUS

CN 1,3,4-Oxadiazole-2-propanoic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-38-1 CAPLUS

CN 5-Thiazolepropanoic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-39-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-40-5 CAPLUS

CN 5-Thiazolepropanoic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-41-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-42-7 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840494-05-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840494-06-6 CAPLUS

CN Benzenepropanoic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 171868-39-6 383661-55-0 839725-20-1

839725-23-4 839725-24-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-55-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 839725-20-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetonitrile, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839725-23-4 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-3-[[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]methyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-24-5 CAPLUS

CN 4,1-Benzoxazepine-3-ethanethioamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189059-52-7P 839724-51-5P 839724-52-6P
 839724-54-8P 839724-55-9P 839724-56-0P
 839724-57-1P 839724-58-2P 839724-59-3P
 839724-60-6P 839724-61-7P 839724-62-8P
 839724-63-9P 839724-64-0P 839724-65-1P
 839724-66-2P 839724-67-3P 839724-68-4P
 839724-69-5P 839724-70-8P 839724-71-9P
 839724-72-0P 839724-73-1P 839724-74-2P
 839724-75-3P 839724-76-4P 839724-77-5P
 839724-78-6P 839724-79-7P 839724-80-0P
 839724-81-1P 839724-82-2P 839724-83-3P
 839724-84-4P 839724-85-5P 839724-86-6P
 839724-87-7P 839724-88-8P 839724-89-9P
 839724-90-2P 839724-91-3P 839724-92-4P
 839724-93-5P 839724-94-6P 839724-95-7P
 839724-96-8P 839724-97-9P 839724-98-0P

839724-99-1P 839725-00-7P 839725-01-8P
 839725-02-9P 839725-03-0P 839725-04-1P
 839725-05-2P 839725-06-3P 839725-07-4P
 839725-08-5P 839725-09-6P 839725-10-9P
 839725-11-0P 839725-12-1P 839725-13-2P
 839725-14-3P 839725-15-4P 839725-16-5P
 839725-17-6P 839725-43-8P 839725-44-9P
 839725-45-0P 839725-46-1P 839725-47-2P
 839725-48-3P 839725-49-4P 841236-35-9P
 841236-36-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 189059-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-51-5 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-52-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-54-8 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-55-9 CAPLUS

CN 4,1-Benzoxazepine-3-ethanethioic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-56-0 CAPLUS

CN Butanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]thio]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-57-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-58-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-59-3 CAPLUS

CN 4,1-Benzoxazepine-3-ethanethioamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-60-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-61-7 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


.Absolute stereochemistry.



RN 839724-62-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-63-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- β -hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-64-0 CAPLUS

CN 2-Propenoic acid, 3-[2-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-65-1 CAPLUS

CN Hexanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5-oxo-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-66-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-67-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-68-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-69-5 CAPLUS

CN 4,1-Benzoxazepine-3-butanoic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro- β ,2-dioxo-, ethyl ester, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-70-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-71-9 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-72-0 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-73-1 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-74-2 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-75-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


.Absolute stereochemistry.



RN 839724-76-4 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(ethoxycarbonyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-77-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2-hydroxyethyl)-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839724-78-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-79-7 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-80-0 CAPLUS

CN Propanedioic acid, monoethyl ester, 2-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-81-1 CAPLUS

CN 1,3,4-Oxadiazole-2-acetic acid, 5-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-82-2 CAPLUS

CN 1,3,4-Thiadiazole-2-acetic acid, 5-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-83-3 CAPLUS

CN Butanedioic acid, monoethyl ester, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-84-4 CAPLUS

CN 1,3,4-Thiadiazole-2-propanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-85-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1,5-dihydro-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-86-6 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid, 3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-87-7 CAPLUS

CN Benzoic acid, 4-[3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-ethoxy-1H-pyrazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-88-8 CAPLUS

CN Benzoic acid, 4-[3-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-89-9 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 3-[2-(4-bromophenyl)-2-oxoethyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-90-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-91-3 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-92-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-93-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-[2-(4-hydroxyphenyl)-2-oxoethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-94-6 CAPLUS

CN Benzeneacetic acid, 4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-95-7 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-96-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-97-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-98-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-99-1 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -(hydroxyphenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-00-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- α -(phenylmethylene)-, ethyl ester, (α Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-01-8 CAPLUS

CN 4,1-Benzoxazepine-3-propanenitrile, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839725-02-9 CAPLUS

CN 4,1-Benzoxazepine-3-propanethioamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839725-03-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetaldehyde, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-04-1 CAPLUS

CN 4-Thiazolepropanenitrile, 2-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-α-[[(1,1-dimethylethyl)dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-05-2 CAPLUS

CN 4,1-Benzoxazepine-3-propanethioamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)- α -[[1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-06-3 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-07-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-08-5 CAPLUS

CN 2-Butenoic acid, 4-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-09-6 CAPLUS

CN 4,1-Benzoxazepine-3-butanoic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839725-10-9 CAPLUS

CN 4,1-Benzoxazepine-3-butanenitrile, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 839725-11-0 CAPLUS

CN 4,1-Benzoxazepine-3-butanethioamide, 1-[2-(acetyloxy)-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-12-1 CAPLUS

CN 1,2,4-Oxadiazole-5-acetonitrile, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-13-2 CAPLUS

CN 4,1-Benzoxazepine-3-ethanimidamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-14-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-15-4 CAPLUS

CN Ethanethioic acid, O-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-16-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-3-[(5-chloro-1,2,4-thiadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-17-6 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-43-8 CAPLUS

CN Propanoic acid, 2-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-44-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-45-0 CAPLUS

CN 2-Butenenitrile, 4-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-46-1 CAPLUS

CN 4,1-Benzoxazepine-3-butanimidamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-hydroxy-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-47-2 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-48-3 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-49-4 CAPLUS

CN 1,3,4-Oxadiazole-2-propanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-35-9 CAPLUS

CN 4,1-Benzoxazepine-3-ethanimidamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-, (3R, 5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-36-0 CAPLUS

CN 4,1-Benzoxazepine-3-propanimidamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-α-[[[1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-, (3R, 5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:902194 CAPLUS

DOCUMENT NUMBER: 141:395590

TITLE: Preparation of benzoxazepine compounds as RFRP receptor antagonists

INVENTOR(S): Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Mabuchi, Hiroshi; Yoshida, Hiromi; Matsumoto, Hirokazu; Wakabayashi, Takeshi

PATENT ASSIGNEE(S): Takeda Chemical Industries Ltd., Japan

SOURCE: PCT Int. Appl., 226 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091628	A1	20041028	WO 2004-JP5406	20040415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004331659	A2	20041125	JP 2004-120246	20040415
PRIORITY APPLN. INFO.:			JP 2003-114313	A 20030418
OTHER SOURCE(S):	MARPAT	141:395590		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted aromatic ring; B = (un)substituted benzene ring; X = O, S(:O)n, NR₃; n = 0-2; R₃ = H, (un)substituted hydrocarbon group, etc.; R₁, R₂ = H, (un)substituted hydrocarbon group, etc.] were prepared For example, reductive amination of compound trans-II·HCl [Q = H] with 3-phenylpropanaldehyde afforded compound trans-II·HCl [Q = 3-phenylpropyl]. In human RFRP-3 (RFamide-related peptide-3) binding inhibition assays, the IC₅₀ value was <1 μM. Compds. I are claimed useful as analgesics, prolactin secretion regulators, etc. Formulations are given.

IT 782466-03-9P 782466-05-1P 782466-07-3P
782466-49-3P 782466-51-7P 782466-55-1P
782466-61-9P 782466-67-5P 782466-69-7P
782466-71-1P 782466-75-5P 782466-77-7P
782467-32-7P 782467-34-9P 782467-38-3P
782467-40-7P 782467-45-2P 782467-51-0P,
trans-[7-Chloro-1-(2,2-dimethylpropyl)-5-(2-methoxy-3-[3-[methyl (3-phenylpropyl)amino]propoxy]phenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetic acid ethyl ester hydrochloride

782467-55-4P 782467-57-6P 782467-59-8P

782467-65-6P 782467-67-8P 782467-71-4P

782468-11-5P 782468-62-6P 782469-59-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-03-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-05-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 782466-07-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-49-3 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-51-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-55-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-61-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl](3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-67-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 782466-69-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-71-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, ethyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-75-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198


Relative stereochemistry.



RN 782466-77-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl] (3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-32-7 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-34-9 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 782467-38-3 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-3-[2-[[[2-(fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 782467-51-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, ethyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-55-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-57-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl] [(1,1-dimethylethoxy) carbonyl] amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl

ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-59-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl][(1,1-dimethylethoxy)carbonyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-65-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-67-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 782467-71-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, 4-piperidinyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

NAME)

Relative stereochemistry.




● HCl

RN 782468-11-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-62-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-59-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 782466-09-5P 782466-11-9P 782466-13-1P
 782466-15-3P 782466-17-5P 782466-19-7P
 782466-21-1P 782466-23-3P 782466-25-5P
 782466-27-7P 782466-29-9P 782466-31-3P
 782466-33-5P 782466-35-7P 782466-37-9P
 782466-39-1P 782466-41-5P 782466-43-7P
 782466-45-9P 782466-47-1P 782466-53-9P
 782466-57-3P 782466-59-5P 782466-73-3P
 782466-79-9P 782466-81-3P 782466-83-5P
 782466-85-7P 782466-87-9P 782466-89-1P
 782466-91-5P 782466-93-7P 782466-95-9P
 782466-97-1P 782466-99-3P 782467-01-0P

782467-03-2P 782467-05-4P 782467-07-6P
 782467-09-8P 782467-11-2P 782467-13-4P
 782467-15-6P 782467-17-8P 782467-19-0P
 782467-21-4P 782467-23-6P 782467-25-8P
 782467-28-1P 782467-30-5P 782467-36-1P
 782467-42-9P 782467-47-4P 782467-53-2P
 782467-61-2P 782467-63-4P 782467-69-0P
 782467-73-6P 782467-75-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-09-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(pentylamino)propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-11-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(phenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-13-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-5-[3-[3-[(2-furanylmethyl)amino]propoxy]-2-methoxyphenyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 782466-15-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-thienylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

Relative stereochemistry.




● HCl

RN 782466-17-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-pyridinylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 782466-19-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride,

10/256,198

(3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-21-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(1-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-23-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-

fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(4-phenylbutyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-25-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(4-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-27-7 CAPLUS

10/256,198

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(3-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-29-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-31-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 782466-33-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-

10/256,198

(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-35-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenylethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 782466-37-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2E)-3-phenyl-2-propenyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-

10/256,198

(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● HCl

RN 782466-39-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(4-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● HCl

—OMe

RN 782466-41-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(3-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

—OMe

RN 782466-43-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[3-(2-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-45-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(3,4-dimethoxyphenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B


 ---OMe

RN 782466-47-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[3-[[2-(1H-indol-3-yl)ethyl]amino]propoxy]-2-methoxyphenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

PAGE 1-A



PAGE 1-B


● HCl



RN 782466-53-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-57-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-(4-phenylbutyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-59-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[methyl(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-73-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 5-[3-[3-[bis(3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-79-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-81-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-83-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-85-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-phenylethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-87-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-N-methyl-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-89-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-phenyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-91-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-pyridinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

Relative stereochemistry.




● 2 HCl

RN 782466-93-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-95-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N,N-diethyl-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-97-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-99-3 CAPLUS

CN Piperidine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-01-0 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-03-2 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-05-4 CAPLUS

CN Morpholine, 4-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-07-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(4-piperidinylmethyl)-, dihydrochloride, (3R, 5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-09-8 CAPLUS

CN 1,4'-Bipiperidine, 1'-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-11-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(2-aminoethyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R, 5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

Relative stereochemistry.




● 2 HCl

RN 782467-13-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl


RN 782467-15-6 CAPLUS

CN 4-Piperidinamine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-

10/256,198

4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-17-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hexahydro-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-19-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-1-(2,2-dimethylpropyl)-1,5-dihydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-3-[2-oxo-2-(4-piperidinyl)ethyl]-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-21-4 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-23-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-(dimethylamino)propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

Relative stereochemistry.




● HCl

RN 782467-25-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-28-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-30-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)ethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-36-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198


Relative stereochemistry.



RN 782467-42-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 782467-47-4 CAPLUS

CN 4,1-Benzoxazepine-1,3(5H)-diacetic acid, 7-chloro-2,3-dihydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, α 3-methyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

Relative stereochemistry.




● HCl

RN 782467-53-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-61-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 782467-63-4 CAPLUS
 CN Piperazine, 1-[[(3R, 5S) -7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-69-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-73-6 CAPLUS

CN 4-Piperidinol, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-75-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

IT 782468-96-6 782469-00-5 782469-02-7

782469-04-9 782469-06-1 782469-52-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782468-96-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-00-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2E)-3-phenyl-2-propenyl]amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 782469-02-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-04-9 CAPLUS

CN Piperidine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-06-1 CAPLUS

CN 4-Piperidinol, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



IT 737784-68-8P 737784-69-9P 737784-70-2P
782467-44-1P 782468-13-7P 782468-15-9P
782468-17-1P 782468-25-1P 782468-27-3P
782468-29-5P 782468-31-9P 782468-33-1P
782468-35-3P 782468-39-7P 782468-41-1P
782468-43-3P 782468-50-2P 782468-54-6P
782468-56-8P 782468-58-0P 782468-60-4P
782468-88-6P 782468-90-0P 782468-92-2P
782469-51-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of benzoxazepine compds. as agents for controlling function of
RFRP receptor)

RN 737784-68-8 CAPLUS

10/256,198

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-69-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-70-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-44-1 CAPLUS

CN 4,1-Benzoxazepine-1,3(5H)-diacetic acid, 7-chloro-2,3-dihydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, α 1-(1,1-dimethylethyl) α 3-methyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-13-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-15-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-nitrophenyl)sulfonyl](2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-17-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-25-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-27-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-29-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-31-9 CAPLUS

CN Glycine, N-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-33-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-35-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-1-methyl-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-39-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, methyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-43-3 CAPLUS

CN 4,1-Benzoxazepine-1,3(5H)-diacetic acid, 7-chloro-2,3-dihydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, α 1-(1,1-dimethylethyl) α 3-methyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-50-2 CAPLUS

CN 4,1-Benzoxazepine-1,3(5H)-diacetic acid, 7-chloro-2,3-dihydro-5-[2-methoxy-3-[3-[[[(2-nitrophenyl)sulfonyl](3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, α 1-(1,1-dimethylethyl) α 3-methyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-54-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 782468-56-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, 4-piperidiny ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-58-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[[[(1,1-dimethylethoxy) carbonyl] (3-phenylpropyl) amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-60-4 CAPLUS

CN 1,2-Piperazinedicarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[[[(1,1-dimethylethoxy) carbonyl] (3-phenylpropyl) amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-88-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-
1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, ethyl
ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-90-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-
1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-,
(3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-92-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 782469-51-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)

10/256,198

Relative stereochemistry.



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

14 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:648392 CAPLUS

DOCUMENT NUMBER: 141:190808

TITLE: Preparation of aromatic ring-fused cyclic compounds as TGR5 receptor agonists

INVENTOR(S): Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Miki, Takashi; Kawamata, Yuji; Oi, Satoru; Tawaraishi, Taisuke; Ishichi, Yuji; Hirohashi, Mariko

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 337 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067008	A1	20040812	WO 2004-JP706	20040127
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
JP 2004346059	A2	20041209	JP 2004-18643	20040127
PRIORITY APPLN. INFO.:			JP 2003-19272	A 20030128
			JP 2003-124311	A 20030428
OTHER SOURCE(S):		MARPAT 141:190808		
GI				



AB It is intended to provide G protein-coupled receptor (TGR5) agonists containing fused ring compds. represented by the following general formula (I), salts or prodrugs thereof (wherein the ring A represents an optionally substituted aromatic ring; and the ring B represents a 5- to 8-membered ring having one or more substituents). Also disclosed are regulators for physiol. functions involving TGR5, preventives and/or remedies for various diseases involving TGR5, cytokine production inhibitors, GLP-1 secretion promoters, insulin secretion promoters, appetite depressants, pancreas regenerants, promoters for pancreas β -cell differentiation or proliferation, insulin resistance improvers, or immunosuppressants. containing the compds. I. In particular disclosed are preventives and/or remedies containing the compds. I for heart failure, myocardial infarction, acute kidney failure, angina pectoris, arrhythmia, bronchial asthma, chronic obstructive pulmonary disease, arteriosclerosis, chronic articular rheumatism, diabetes, obesity, insulin secretion failure, pancreas fatigue, gastric ulcer, ulcerative colitis, allergy, osteoarthritis, erythematodes, or excessive immune reaction after transplant surgery. The compds. I are also useful for screening ligands,

agonists, or antagonists of TGR5. Thus, 0.1 g 2-[trans-7-chloro-5-(3-formylphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide was reduced by NaBH₄ in MeOH at room temperature for 30 min to give 76 mg 2-[trans-7-chloro-5-(3-hydroxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide (II). II at 1 μ M increased the production of cAMP in CHO cells expressing human TGR5 by 128%. Pharmaceutical formulations containing specific compound I were also prepared

IT 737785-03-4P 737785-06-7P 737785-08-9P

737785-09-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists, cytokine production inhibitors and appetite depressants)

RN 737785-03-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-amino-2-oxoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-06-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)-2-oxoethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-08-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-oxo-2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-09-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethoxy]-2-methoxyphenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 737784-68-8P 737784-69-9P 737784-70-2P
737784-72-4P 737784-73-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,

cytokine production inhibitors and appetite depressants)

RN 737784-68-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-69-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-70-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-72-4 CAPLUS

CN Acetic acid, [3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-73-5 CAPLUS

CN Acetic acid, [3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



LA ANSWER 6 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:633548 CAPLUS

DOCUMENT NUMBER: 141:162403

TITLE: Skeletal muscle protecting agents containing squalene synthase inhibitors

INVENTOR(S): Tozawa, Ryuichi; Nishimoto, Tomoyuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064865	A1	20040805	WO 2004-JP234	20040115
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				
JP 2003277377	A2	20031002	JP 2003-10125	20030117
PRIORITY APPLN. INFO.:			JP 2003-10125	A 20030117
			JP 2003-93591	A 20030331
			JP 2002-10623	A 20020118

OTHER SOURCE(S): MARPAT 141:162403

AB It is intended to provide a novel drug useful as a skeletal muscle protecting agent which contains a compound having an effect of inhibiting squalene synthase, its salt or a prodrug thereof. The agent of the present invention is suitable for use for protecting skeletal muscle from cytotoxicity due to usage of other drug, e.g. HMG-CoA reductase inhibitor. The effect of N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid on muscle geranylgeraniol content in rats was examined

IT 189059-71-0 189060-13-7 383652-98-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(skeletal muscle protecting agents containing squalene synthase inhibitors)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:885310 CAPLUS

DOCUMENT NUMBER: 140:174823

TITLE: Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes

AUTHOR(S): Nishimoto, Tomoyuki; Tozawa, Ryuichi; Amano, Yuichiro; Wada, Takeo; Imura, Yoshimi; Sugiyama, Yasuo

CORPORATE SOURCE: Pharmaceutical Research Division, Pharmacology Research Laboratories I, Takeda Chemical Industries, Ltd., Yodogawa-ku, Osaka, 532-8686, Japan

SOURCE: Biochemical Pharmacology (2003), 66(11), 2133-2139
CODEN: BCPA6; ISSN: 0006-2952

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB TAK-475 is a squalene synthase inhibitor, rapidly metabolized to T-91485 in vivo. We investigated the myotoxicities of T-91485 and 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors in a human rhabdomyosarcoma cell line, RD, and in human skeletal myocytes. In differentiated RD cells, T-91485, atorvastatin (ATV) and simvastatin acid (SIM) inhibited cholesterol biosynthesis, with ic50 values of 36, 2.8 and 3.8 nM, resp. ATV and SIM decreased the intracellular ATP content, with ic25 values (concns. giving a 25% decrease in intracellular ATP content) of 0.61 and 0.44 μ M, resp. Although T-91485 potently inhibited cholesterol synthesis in RD cells, the ic25 value exceeded 100 μ M. In human skeletal myocytes, T-91485, ATV and SIM concentration-dependently inhibited

cholesterol biosynthesis, with ic50 values of 45, 8.6 and 8.4 nM, resp. ATV and SIM decreased intracellular ATP content, with ic25 values of 2.1 and 0.72 μ M, resp. Although T-91485 potently inhibited cholesterol synthesis, the ic25 value exceeded 100 μ M. Myotoxicity induced by ATV was prevented by mevalonate or geranylgeranyl-PP, but not by squalene in skeletal cells. Furthermore, T-91485 attenuated the myotoxicity of ATV. These findings suggest that TAK-475 and T-91485 may not only be far from myotoxic, they may also decrease statin-induced myotoxicity in lipid-lowering therapy.


IT 189059-71-0, T 91485

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors in human myocytes)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

35

THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

14 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:767796 CAPLUS

DOCUMENT NUMBER: 139:276921

TITLE: Preparation of benzoxazepine derivatives as squalene synthetic enzyme inhibitors

INVENTOR(S): Miki, Takashi; Kori, Masaki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003277377	A2	20031002	JP 2003-10125	20030117
WO 2004064865	A1	20040805	WO 2004-JP234	20040115
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				
JP 2004107361	A2	20040408	JP 2004-9836	20040116
JP 2004315500	A2	20041111	JP 2004-9617	20040116
PRIORITY APPLN. INFO.:			JP 2002-10623	A 20020118
			JP 2003-10125	A 20030117
			JP 2003-93591	A 20030331
OTHER SOURCE(S):		MARPAT 139:276921		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [wherein W = halo; R1 = alkyl; R2 = CHO or (un)substituted alkyl; m = 1-3; n = 0-2; R4 = H or -(CH2)p-R5; R5 = (un)substituted CO2H; p = 0-3; etc.] and salts and prodrugs thereof are prepared as squalene synthetic enzyme inhibitors. I are useful as a lipid decrease medicine and a high fat blood disease medicine (no data). Thus, the compound II was prepared in a multi-step synthesis. II showed IC50 of 45 nM against human squalene synthetic enzyme. Formulations containing I as an active ingredient were also described.

IT 606928-79-4P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-79-4 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 606928-80-7P 606928-81-8P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-80-7 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 606928-81-8 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 606928-73-8P 606928-75-0P 606928-77-2P
606928-78-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-73-8 CAPLUS

CN 4-Pyridineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,6-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-75-0 CAPLUS

CN Pyridine, 1-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-77-2 CAPLUS

CN 4-Pyridineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethyl-3-oxopropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-78-3 CAPLUS

CN 4-Pyridineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 383652-98-0P 606928-74-9P 606928-76-1P
606929-11-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic
enzyme inhibitors)

RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-
3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 606928-74-9 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-
3-yl]acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-76-1 CAPLUS

CN Pyridine, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606929-11-7 CAPLUS

CN 4-Pyridineacetic acid, 1-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 606928-85-2P 606928-96-5P 606928-97-6P
 606928-98-7P 606929-00-4P 606929-01-5P
 606929-02-6P 606929-03-7P 606929-04-8P
 606929-06-0P 606929-07-1P 606929-08-2P
 606929-09-3P 606929-10-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of benzoxazepine derivs. as squalene synthetic
 enzyme inhibitors)

RN 606928-85-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-
 chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(5-hydroxypentyl)-2-
 oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 606928-96-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-
 tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(tetrahydro-2-oxo-
 2H-pyran-4-yl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)

10/256,198


Absolute stereochemistry.



RN 606928-97-6 CAPLUS

CN Pentanoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-5-hydroxy-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 606928-98-7 CAPLUS

CN Pentanoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-5-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606929-00-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-01-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-02-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-03-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-04-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-06-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-07-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-08-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-09-3 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-10-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 189060-51-3 383661-55-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 189060-51-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-55-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



14 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:584090 CAPLUS

DOCUMENT NUMBER: 139:240092

TITLE: Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

AUTHOR(S): Nishimoto, Tomoyuki; Amano, Yuichiro; Tozawa, Ryuichi; Ishikawa, Eiichiro; Imura, Yoshimi; Yukimasa, Hidefumi; Sugiyama, Yasuo

CORPORATE SOURCE: Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, 532-8686, Japan

SOURCE: British Journal of Pharmacology (2003), 139(5), 911-918

CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We examined the lipid-lowering properties of 1-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid (TAK-475), a novel squalene synthase inhibitor. TAK-475 inhibited hepatic cholesterol biosynthesis in rats (ED₅₀, 2.9 mg kg⁻¹) and showed lipid-lowering effects in beagle dogs, marmosets, cynomolgus monkeys and Wistar fatty rats. In marmosets, TAK-475 (30, 100 mg kg⁻¹, p.o., for 4 days) lowered both plasma non-high-d. lipoprotein (HDL) cholesterol and triglyceride, but did not affect plasma HDL cholesterol. Atorvastatin (10, 30 mg kg⁻¹, p.o., for 4 days) lowered the levels of all these lipids. A correlation between decrease in triglyceride and increase in HDL cholesterol was observed, and TAK-475 increased HDL cholesterol with a smaller decrease in triglyceride than did atorvastatin. TAK-475 (60 mg kg⁻¹, p.o., for 15 days) suppressed the rate of triglyceride secretion from the liver in hypertriglyceridemic Wistar fatty rats, which show an enhanced triglyceride secretion rate from the liver compared with their lean littermates. In HepG2 cells, TAK-475 and its pharmacol. active metabolite, T-91485, increased the binding of ¹²⁵I-low-d. lipoprotein (LDL) to LDL receptors. These results suggest that TAK-475 has clear hypolipidemic effects in animals via inhibition of hepatic triglyceride secretion and upregulation of LDL receptors, and that TAK-475 might increase HDL cholesterol by decreasing triglyceride. Thus, TAK-475 is expected to be useful for the treatment of dyslipidemia.


IT 189060-13-7, TAK 475

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lipid-lowering properties of TAK-475)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **189059-71-0**

RL: PAC (Pharmacological activity); BIOL (Biological study)
(lipid-lowering properties of TAK-475)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-
3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

L4 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:249806 CAPLUS

DOCUMENT NUMBER: 139:173582

TITLE: Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia

AUTHOR(S): Amano, Yuichiro; Nishimoto, Tomoyuki; Tozawa, Ryu-Ichi; Ishikawa, Eiichiro; Imura, Yoshimi; Sugiyama, Yasuo

CORPORATE SOURCE: Pharmaceutical Research Division, Pharmacology Research Laboratories II, Takeda Chemical Industries, Ltd., 2-17-85, Juso-Honmachi, Osaka, Yodogawa, 532-8686, Japan

SOURCE: European Journal of Pharmacology (2003), 466(1-2), 155-161

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The lipid-lowering effects of 1-{2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-(2,3-dimethoxyphenyl)-4,1-benzoxazepine-3-yl] acetyl} piperidin-4-acetic acid (TAK-475), a novel squalene synthase inhibitor, were examined in two models of familial hypercholesterolemia, low-d. lipoprotein (LDL) receptor knockout mice and Watanabe heritable hyperlipidemic (WHHL) rabbits. Two weeks of treatment with TAK-475 in a diet admixt. (0.02% and 0.07%; approx. 30 and 110 mg/kg/day, resp.) significantly lowered plasma non-high-d. lipoprotein (HDL) cholesterol levels by 19% and 41%, resp., in homozygous LDL receptor knockout mice. The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors, simvastatin and atorvastatin (in 0.02% and 0.07% admixts.), also reduced plasma levels of non-HDL cholesterol. In homozygous WHHL rabbits, 4 wk of treatment with TAK-475 (0.27%; approx. 100 mg/kg/day) lowered plasma total cholesterol, triglyceride and phospholipid levels by 17%, 52% and 26%, resp. In Triton WR-1339-treated rabbits, TAK-475 inhibited to the same extent the rate of secretion from the liver of the cholesterol, triglyceride and phospholipid components of very-low-d. lipoprotein (VLDL). These results suggest that the lipid-lowering effects of TAK-475 in WHHL rabbits are based partially on the inhibition of secretion of VLDL from the liver. TAK-475 had no effect on plasma aspartate aminotransferase and alanine aminotransferase activities. Thus, the squalene synthase inhibitor TAK-475 revealed lipid-lowering effects in both LDL receptor knockout mice and WHHL rabbits.

IT 189060-13-7, TAK 475

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

32

Page 226

L4 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:22711 CAPLUS

DOCUMENT NUMBER: 138:83384

TITLE: Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase

INVENTOR(S): Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002147	A1	20030109	WO 2002-JP6495	20020627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2451163	AA	20030109	CA 2002-2451163	20020627
JP 2003081873	A2	20030319	JP 2002-188133	20020627
EP 1407782	A1	20040414	EP 2002-738822	20020627
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004204500	A1	20041014	US 2003-480707	20031211
PRIORITY APPLN. INFO.:			JP 2001-197419	A 20010628
			WO 2002-JP6495	W 20020627

OTHER SOURCE(S): MARPAT 138:83384

AB Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same.

IT **383652-98-0P**


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 383652-98-0 CAPLUS


CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **171868-39-6 189058-78-4**, N-[[[(3R,5S)-1-(2,2-Dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetic acid **189059-19-6**
189059-57-2 189059-71-0, N-[[[(3R,5S)-1-(3-Hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetic acid **189059-84-5**
189059-85-6 189060-04-6, Ethyl N-[[[(3R,5S)-1-(3-Acetoxy-2-acetoxy-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetate
189060-07-9 189060-10-4, Ethyl N-[[[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidineacetate
189060-21-7 189060-33-1 189060-37-5
189060-41-1 189060-45-5 189060-48-8
383652-05-9 383652-11-7 383652-16-2
383652-22-0 383652-28-6 383652-33-3
383652-38-8 383652-44-6, Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- **383652-50-4 383652-56-0 383652-61-7**
383652-66-2 383652-71-9 383652-76-4
383652-81-1 383652-87-7 383652-92-4
383654-65-7, Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- **383657-83-8**
383662-50-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)
 RN **171868-39-6** CAPLUS
 CN **4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)**


Absolute stereochemistry. Rotation (-).



RN 189058-78-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-57-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-84-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189060-07-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-21-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-33-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-45-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-48-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-05-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-11-7 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-16-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-22-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-28-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-33-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-38-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-44-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-50-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-56-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-61-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-66-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-71-9 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-76-4 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-81-1 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-87-7 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-92-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-65-7 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-50-8 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **189060-51-3P**, (3R,5S)-7-Chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-4,1-benzoxazepin-3-acetic acid **383654-76-0P**


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 189060-51-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-76-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 189060-13-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

38

THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:664428 CAPLUS

DOCUMENT NUMBER: 137:337866

TITLE: Synthesis of Novel 4,1-Benzoxazepine Derivatives as Squalene Synthase Inhibitors and Their Inhibition of Cholesterol Synthesis

AUTHOR(S): Miki, Takashi; Kori, Masakuni; Mabuchi, Hiroshi; Tozawa, Ryu-ichi; Nishimoto, Tomoyuki; Sugiyama, Yasuo; Teshima, Koichiro; Yukimasa, Hidefumi

CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Yodogawa-ku, Osaka, 532-8686, Japan

SOURCE: Journal of Medicinal Chemistry (2002), 45(20), 4571-4580

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:337866

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Modification of the carboxyl group at the 3-position and introduction of protective groups to the hydroxy group of the 4,1-benzoxazepine derivative I (R = OH) [metabolite of I (R = H) Na salt] were carried out, and the inhibitory activity for squalene synthase and cholesterol synthesis in the liver was investigated. Among these compds., the glycine derivative II (n = 1) and β -alanine derivative II (n = 2) exhibited the most potent inhibition of squalene synthase prepared from HepG2 cells (IC₅₀ = 15 nM). On the other hand, the piperidine-4-acetic acid derivative III (R₁ = Ac), which was prepared by acetylation of III (R₁ = H), was the most effective inhibitor of cholesterol synthesis in rat liver (ED₅₀ = 2.9 mg/kg, po). After oral administration, III (R₁ = Ac) was absorbed and rapidly hydrolyzed to III (R₁ = H). Compound III (R₁ = H) was detected mainly in the liver, but the plasma level of III (R₁ = H) was found to be low. Compds. III (R₁ = H, Ac) were found to be competitive inhibitors with respect to farnesyl pyrophosphate. Further evaluation of III (R₁ = Ac) as a cholesterol-lowering and antiatherosclerotic agent is underway.

IT 189059-71-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and their inhibition of cholesterol synthesis)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189059-72-1P 189060-13-7P 383653-71-2P
 383654-03-3P 383654-14-6P 383658-74-0P
 383658-84-2P 473987-15-4P 473987-16-5P
 473987-17-6P 473987-18-7P 473987-19-8P
 473987-25-6P 473987-26-7P 473987-27-8P
 473987-28-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)

(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and their
 inhibition of cholesterol synthesis)

RN 189059-72-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-
 1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-
 3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-
 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-
 3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-71-2 CAPLUS

CN D-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-03-3 CAPLUS

CN L-Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-14-6 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-74-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-84-2 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-15-4 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-16-5 CAPLUS

CN Glycine, N-[[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-17-6 CAPLUS

CN β -Alanine, N-[[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-18-7 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-19-8 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-25-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-26-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxobutoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-27-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(2-methyl-1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-28-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[(2,2-dimethyl-1-oxopropoxy)methoxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 189059-61-8P 189059-65-2P 189059-66-3P
 189060-51-3P 383661-79-8P 383662-10-0P
 383662-15-5P 383669-08-7P 383669-14-5P
 473987-08-5P 473987-09-6P 473987-10-9P
 473987-13-2P 473987-14-3P 473987-20-1P
 473987-21-2P 473987-22-3P 473987-23-4P
 473987-24-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and their inhibition of cholesterol synthesis)

RN 189059-61-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, ethyl ester, (3R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-

10/256,198

1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-66-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-51-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-79-8 CAPLUS

CN D-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383662-10-0 CAPLUS

CN L-Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-15-5 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-08-7 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-14-5 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-08-5 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-09-6 CAPLUS

CN Glycine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-10-9 CAPLUS

CN β -Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-13-2 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-14-3 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-20-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473987-21-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-22-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxobutoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-23-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(2-methyl-1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-24-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[(2,2-dimethyl-1-oxopropoxy)methoxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:368342 CAPLUS

DOCUMENT NUMBER: 136:359669

TITLE: High-density lipoprotein-cholesterol level elevating agent

INVENTOR(S): Nishimoto, Tomoyuki; Tozawa, Ryuichi; Kori, Masakuni; Amano, Yuichiro

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038180	A1	20020516	WO 2001-JP9802	20011109
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2428669	AA	20020516	CA 2001-2428669	20011109
AU 2002012741	A5	20020521	AU 2002-12741	20011109
JP 2002205956	A2	20020723	JP 2001-344074	20011109
EP 1332763	A1	20030806	EP 2001-981043	20011109
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004063750	A1	20040401	US 2003-416239	20030506
PRIORITY APPLN. INFO.:			JP 2000-342607	A 20001109
			WO 2001-JP9802	W 20011109

OTHER SOURCE(S): MARPAT 136:359669

AB Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined. Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 40, hydroxypropyl cellulose 5.5, and magnesium stearate 0.6 mg was prepared.

IT 189060-05-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)

RN 189060-05-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 171868-39-6 189058-97-7 189059-19-6
 189059-57-2 189059-70-9 189059-84-5
 189059-85-6 189060-04-6 189060-07-9
 189060-10-4 189060-13-7 189060-21-7
 189060-33-1 189060-37-5 189060-45-5
 189060-48-8 383652-05-9 383652-11-7
 383652-22-0 383652-28-6 383652-33-3
 383652-38-8 383652-44-6 383652-50-4
 383652-66-2 383652-71-9 383652-76-4
 383652-81-1 383652-92-4 383652-98-0
 383654-76-0 383657-83-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (high-d. lipoprotein-cholesterol level elevating agents containing squalene
 synthase inhibitors)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-
 dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 189058-97-7 CAPLUS

CN β -Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

10/256,198

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-57-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-84-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-07-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-21-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-33-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-45-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-48-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-05-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-11-7 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-22-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-28-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-33-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


.Absolute stereochemistry. Rotation (-).



RN 383652-38-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-44-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-50-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-66-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-71-9 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-76-4 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-81-1 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-92-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-76-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:19789 CAPLUS

DOCUMENT NUMBER: 136:369691

TITLE: 4,1-Benzoxazepine derivatives as squalene synthase inhibitors. 4. Microbial enantioselective ester hydrolysis for the preparation of optically active 4,1-benzoxazepine-3-acetic acid derivatives as squalene synthase inhibitors

AUTHOR(S): Tarui, Naoki; Nakahama, Kazuo; Nagano, Yoichi; Izawa, Motowo; Matsumoto, Kiyoharu; Kori, Masakuni; Nagata, Toshiaki; Miki, Takashi; Yukimasa, Hidefumi

CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Yodogawa-ku. Osaka, 532-8686, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2002), 50(1), 59-65

CODEN: CPBTAL; ISSN: 0009-2363


PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:369691

GI



AB Microbial enantioselective ester hydrolysis for the preparation of optically active (3R,5S)-(-)-5-phenyl-4,1-benzoxazepine-3-acetic acid derivs. as potent squalene synthase inhibitors was investigated. *Pseudomonas diminuta* and *Pseudomonas taetrolens* hydrolyzed the racemic Et ester of a 5-(2-chlorophenyl) analog to yield a (-)-carboxylic acid with excellent enantiomeric excess (>99% ee). The (-)-enantiomer was found to be an active inhibitor. Bulkiness of the ester moiety did not affect the enantioselectivity but did affect reactivity. The racemic Et esters of the 5-(2-methoxyphenyl) analog, 5-(2,3-dimethoxyphenyl) analog and 5-(2,4-dimethoxyphenyl) analog were also hydrolyzed with *Pseudomonas taetrolens* to afford enantiomerically pure (-)-carboxylic acids in large scale. As another route to (3R,5S)-(-)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid (I), an earlier intermediate (-)-2-amino-5-chloro- α -(2,3-dimethoxyphenyl)benzyl alc. was successfully obtained by asym. hydrolysis of (\pm)-5-chloro- α -(2,3-dimethoxyphenyl)-2-pivaloylaminobenzyl acetate with *Pseudomonas* sp. S-13 with >99% ee in kilogram scale followed by, alkaline treatment. The product was converted to I without racemization.


IT **171868-39-6P**

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(microbial enantioselective ester hydrolysis for the preparation of optically active 4,1-benzoxazepine-3-acetic acid derivs. as squalene synthase inhibitors)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


IT **177567-40-7P**

RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(microbial enantioselective ester hydrolysis for the preparation of optically active 4,1-benzoxazepine-3-acetic acid derivs. as squalene synthase inhibitors)

RN 177567-40-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 152909-22-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(microbial enantioselective ester hydrolysis for the preparation of optically active 4,1-benzoxazepine-3-acetic acid derivs. as squalene synthase inhibitors)

RN 152909-22-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

LA ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:935587 CAPLUS

DOCUMENT NUMBER: 136:69829

TITLE: Preparation of dialkoxypheylloxobenzoxazepineacetamide
squalene synthase inhibitors as antihyperlipidemic and
antihypercholesteremic agents

INVENTOR(S): Kori, Masakuni; Miki, Takashi; Nishimoto, Tomoyuki;
Tozawa, Ryuichi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd, Japan

SOURCE: PCT Int. Appl., 643 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098282	A1	20011227	WO 2001-JP5347	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413429	AA	20011227	CA 2001-2413429	20010622
AU 2001074588	A5	20020102	AU 2001-74588	20010622
JP 2002080468	A2	20020319	JP 2001-189417	20010622
JP 2003064063	A2	20030305	JP 2002-233086	20010622
EP 1292585	A1	20030319	EP 2001-941174	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011835	A	20030429	BR 2001-11835	20010622
US 2003078251	A1	20030424	US 2002-203524	20020809
ZA 2002009055	A	20031107	ZA 2002-9055	20021107
NO 2002006164	A	20021220	NO 2002-6164	20021220
PRIORITY APPLN. INFO.:			JP 2000-190253	A 20000623
			JP 2001-189417	A3 20010622
			WO 2001-JP5347	W 20010622

OTHER SOURCE(S): MARPAT 136:69829

GI



AB Alkoxyphenyloxobenzoxazepineacetamides [I; R = (un)substituted 1-carboxyethyl, (un)substituted carboxyalkyl, sulfonylalkyl, (carboxycycloalkyl)alkyl, etc.; R1 = alkyl (un)substituted with alkanoyloxy or OH groups (if R = (un)substituted 1-carboxyethyl, alkyl, 4-carboxycyclohexylmethyl, or 4-carboxyphenylmethyl, then R1 must be substituted with a OH or alkanoyloxy group); R2 = lower alkyl; W = halogen] are prepared as squalene synthase inhibitors for the treatment of hyperlipidemia and the decrease of serum triglycerides and lipids. (3R, 4S)-I [R = Me(CH₂)₂SO₂; R1 = HOCH₂C(Me)₂CH₂; R2 = Me; W = Cl] (II) was prepared in 3 steps from hydroxyacid (III) by acetylation of the hydroxyl group with acetic anhydride, treatment of the acid with thionyl chloride in THF to generate the acid chloride in situ, and addition of the mixture to a solution of PrSO₂NH₂ in THF to provide the acetylated methoxyphenyloxobenzoxazepineacetamide I [R = PrSO₂; R1 = AcOCH₂C(Me)₂CH₂; R2 = Me; W = Cl]; hydrolysis of the acetoxy group with aqueous sodium hydroxide and ethanol provides II. Data for the inhibition of squalene synthase by I are given. Pharmaceutical compns. containing I [R = 3-(HO₂CCH₂CH₂)C₆H₄; R1 = HOCH₂CMe₂CH₂; R2 = Me; W = Cl] are specified.

IT 383661-55-0P 383661-74-3P 383661-79-8P
 383661-85-6P 383661-90-3P 383661-95-8P
 383662-00-8P 383662-05-3P 383662-10-0P
 383662-15-5P 383662-20-2P 383662-25-7P
 383662-50-8P 383662-71-3P 383662-81-5P
 383662-97-3P 383663-24-9P 383663-35-2P
 383663-76-1P 383664-02-6P 383664-07-1P
 383664-12-8P 383664-18-4P 383664-35-5P
 383664-54-8P 383664-99-1P 383665-26-7P
 383665-43-8P 383665-48-3P 383665-62-1P
 383665-76-7P 383666-12-4P 383666-22-6P
 383666-37-3P 383666-63-5P 383666-68-0P
 383666-96-4P 383667-27-4P 383667-32-1P
 383667-37-6P 383667-42-3P 383667-47-8P
 383667-52-5P 383667-58-1P 383667-63-8P
 383667-69-4P 383667-74-1P 383667-79-6P
 383667-84-3P 383667-89-8P 383667-94-5P
 383668-00-6P 383668-05-1P 383668-10-8P
 383668-26-6P 383668-39-1P 383668-63-1P
 383668-88-0P 383669-02-1P 383669-08-7P
 383669-14-5P 383669-23-6P 383669-33-8P

383669-42-9P 383669-51-0P 383669-66-7P
 383669-82-7P 383670-03-9P 383670-28-8P
 383670-38-0P 383670-49-3P 383670-59-5P
 383670-64-2P 383670-69-7P 383670-85-7P
 383671-02-1P 383671-23-6P 383671-45-2P
 383671-60-1P 383671-79-2P 383672-12-6P
 383672-25-1P 383672-30-8P 383672-35-3P
 383672-40-0P 383672-50-2P 383672-67-1P
 383672-82-0P 383672-88-6P 383672-95-5P
 383673-01-6P 383673-16-3P 383673-32-3P
 383673-59-4P 383673-75-4P 383674-10-0P
 383674-38-2P 383674-55-3P 383674-72-4P
 383674-89-3P 383674-95-1P 383675-11-4P
 383675-45-4P 383675-68-1P 383675-90-9P
 383676-16-2P 383676-57-1P 383676-81-1P
 383677-02-9P 383677-82-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediates; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383661-55-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-74-3 CAPLUS

CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-79-8 CAPLUS

CN D-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-85-6 CAPLUS

CN D-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-90-3 CAPLUS

CN L-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-95-8 CAPLUS

CN D-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383662-00-8 CAPLUS

CN D-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383662-05-3 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylethyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-10-0 CAPLUS

CN L-Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-15-5 CAPLUS

CN D-Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-20-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-25-7 CAPLUS

CN Cyclohexanepropanoic acid, α -[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383662-50-8 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-71-3 CAPLUS

CN 2,4-Furandicarboxylic acid, 5-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-81-5 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-97-3 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383663-24-9 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383663-35-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383663-76-1 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-02-6 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-07-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-12-8 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-18-4 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-35-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-ethoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-54-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(1-methylethoxy)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-99-1 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383665-26-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-43-8 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-48-3 CAPLUS

CN Benzenecetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-62-1 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-76-7 CAPLUS

CN Benzenecetic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-12-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-22-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383666-37-3 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,5-dimethoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-63-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-68-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-96-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-27-4 CAPLUS

CN Benzoic acid, 4-[[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-32-1 CAPLUS

CN Propanoic acid, 2-[4-[[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-37-6 CAPLUS

CN Acetic acid, [4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-42-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-47-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-52-5 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-58-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-63-8 CAPLUS

CN Benzoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-69-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-74-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-79-6 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-84-3 CAPLUS

CN Benzeneacetic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-89-8 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-94-5 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-00-6 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-05-1 CAPLUS

CN Benzoic acid, 4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-10-8 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-26-6 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383668-39-1 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-63-1 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-88-0 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-02-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-08-7 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-14-5 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-23-6 CAPLUS

CN Hexanoic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-33-8 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383669-42-9 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383669-51-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383669-66-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-chloro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-82-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-(3-phenylpropoxy)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383670-03-9 CAPLUS


CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(3-phenylpropoxy)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 383670-28-8 CAPLUS

CN 1-Naphthalenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-38-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383670-49-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-59-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-64-2 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-69-7 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-85-7 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-02-1 CAPLUS

CN Acetic acid, [3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro-, ethyl ester (9CI) (CA INDEX NAME)


.Absolute stereochemistry. Rotation (-).



RN 383671-23-6 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-45-2 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-60-1 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-fluorophenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-79-2 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- α,α -dimethyl-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-12-6 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- γ,γ -dimethyl-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-25-1 CAPLUS

CN Benzenepentanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-30-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-35-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-40-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-50-2 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-67-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-82-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-88-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-95-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-01-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-16-3 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-32-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-59-4 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-75-4 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-10-0 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-(1-methylethoxy)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-38-2 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-55-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-propoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-72-4 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(2-ethoxy-2-oxoethoxy)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-89-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(1-methylethoxy)-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-95-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-11-4 CAPLUS

CN Benzo[b]thiophene-2-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-45-4 CAPLUS

CN 2-Benzofuranpropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-68-1 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-90-9 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383676-16-2 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383676-57-1 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383676-81-1 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,6,7-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383677-02-9 CAPLUS

CN 2-Benzofurancarboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5-chloro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383767-82-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 189060-51-3 383678-02-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting materials; preparation of dialkoxyphenyloxobenzoxazepineacetamide
squalene synthase inhibitors as antihyperlipidemic and
antihypercholesteremic agents)

RN 189060-51-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383678-02-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 383652-33-3P 383652-44-6P 383652-56-0P
 383652-66-2P 383652-92-4P 383652-98-0P
 383653-04-1P 383653-14-3P 383653-20-1P
 383653-31-4P 383653-40-5P 383653-71-2P
 383654-03-3P 383654-14-6P 383654-54-4P
 383654-65-7P 383654-88-4P 383654-99-7P
 383655-09-2P 383655-19-4P 383655-31-0P
 383655-41-2P 383655-52-5P 383655-73-0P
 383655-93-4P 383656-19-7P 383656-30-2P
 383656-42-6P 383656-68-6P 383656-78-8P
 383656-90-4P 383657-01-0P 383657-12-3P
 383657-22-5P 383657-38-3P 383657-50-9P
 383657-61-2P 383657-72-5P 383657-83-8P
 383657-94-1P 383658-05-7P 383658-15-9P

383658-25-1P 383658-36-4P 383658-46-6P

383658-84-2P 383658-95-5P 383659-31-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383652-33-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-44-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/256,198

RN 383652-56-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-66-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-92-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-04-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-14-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(butylsulfonyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-20-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-N-[[3-(acetyloxy)propyl]sulfonyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-31-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(phenylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-40-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-71-2 CAPLUS

CN D-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-03-3 CAPLUS

CN L-Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-14-6 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-54-4 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-65-7 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-88-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-99-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-09-2 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-19-4 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-31-0 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-41-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-52-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-73-0 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383655-93-4 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-19-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-30-2 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-42-6 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-68-6 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-78-8 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-90-4 CAPLUS

CN Propanoic acid, 2-[4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-01-0 CAPLUS

CN Acetic acid, [4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-12-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-22-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-38-3 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-50-9 CAPLUS

CN Benzoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-61-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-72-5 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-94-1 CAPLUS

CN Benzeneacetic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-05-7 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-15-9 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-25-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-36-4 CAPLUS

CN Benzoic acid, 4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-46-6 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-84-2 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-95-5 CAPLUS

CN Hexanoic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-31-2 CAPLUS

CN Benzenepropanoic acid, 4-chloro-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 383652-05-9P 383652-11-7P 383652-16-2P
 383652-22-0P 383652-28-6P 383652-38-8P
 383652-50-4P 383652-61-7P 383652-71-9P
 383652-76-4P 383652-81-1P 383652-87-7P
 383653-09-6P 383653-25-6P 383653-35-8P
 383653-45-0P 383653-66-5P 383653-76-7P
 383653-81-4P 383653-86-9P 383653-92-7P
 383653-97-2P 383654-09-9P 383654-20-4P
 383654-25-9P 383654-30-6P 383654-36-2P
 383654-41-9P 383654-46-4P 383654-60-2P
 383654-70-4P 383654-76-0P 383654-82-8P
 383654-94-2P 383655-04-7P 383655-14-9P
 383655-25-2P 383655-36-5P 383655-46-7P
 383655-57-0P 383655-78-5P 383655-83-2P

383655-98-9P 383656-06-2P 383656-24-4P
 383656-36-8P 383656-63-1P 383656-73-3P
 383656-84-6P 383656-95-9P 383657-07-6P
 383657-17-8P 383657-27-0P 383657-32-7P
 383657-44-1P 383657-55-4P 383657-67-8P
 383657-78-1P 383657-89-4P 383657-99-6P
 383658-10-4P 383658-20-6P 383658-30-8P
 383658-40-0P 383658-51-3P 383658-57-9P
 383658-62-6P 383658-68-2P 383658-74-0P
 383658-79-5P 383658-90-0P 383659-00-5P
 383659-06-1P 383659-21-0P 383659-26-5P
 383659-37-8P 383659-42-5P 383659-48-1P
 383659-55-0P 383659-61-8P 383659-67-4P
 383659-73-2P 383659-79-8P 383659-84-5P
 383659-89-0P 383659-94-7P 383659-99-2P
 383660-05-7P 383660-11-5P 383660-16-0P
 383660-21-7P 383660-26-2P 383660-32-0P
 383660-38-6P 383660-43-3P 383660-48-8P
 383660-52-4P 383660-57-9P 383660-62-6P
 383660-67-1P 383660-72-8P 383660-77-3P
 383660-82-0P 383660-87-5P 383660-93-3P
 383660-98-8P 383661-03-8P 383661-08-3P
 383661-12-9P 383661-17-4P 383661-22-1P
 383661-27-6P 383661-31-2P 383661-36-7P
 383661-40-3P 383661-45-8P 383661-50-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(title compds.; preparation of dialkoxypheylloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383652-05-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383652-11-7 CAPLUS

CN D-Alanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

10/256,198

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-16-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-22-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-28-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-38-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-50-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-61-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-71-9 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-76-4 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-81-1 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-87-7 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-09-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-N-(butylsulfonyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-25-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-[(3-hydroxypropyl)sulfonyl]-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-35-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(phenylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-45-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-66-5 CAPLUS

CN L-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-76-7 CAPLUS

CN D-Leucine, N-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-81-4 CAPLUS

CN D-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-86-9 CAPLUS

CN L-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-92-7 CAPLUS

CN D-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-97-2 CAPLUS

CN D-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-09-9 CAPLUS

CN L-Alanine, N-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-20-4 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-25-9 CAPLUS

CN Cyclohexanepropanoic acid, α -[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-30-6 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-36-2 CAPLUS

CN 2,4-Furandicarboxylic acid, 5-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-41-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-46-4 CAPLUS

CN 2-Furancarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-60-2 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-70-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-76-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-82-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-94-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-04-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-14-9 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-25-2 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-36-5 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-46-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-57-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-78-5 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383655-83-2 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383655-98-9 CAPLUS

CN Benzenecarboxylic acid, 4-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-06-2 CAPLUS

CN Benzenepropanoic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-24-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-36-8 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-63-1 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-73-3 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-84-6 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-95-9 CAPLUS

CN Propanoic acid, 2-[4-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-07-6 CAPLUS

CN Acetic acid, [4-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-17-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-27-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-32-7 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-44-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-55-4 CAPLUS

CN Benzoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-67-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-78-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-89-4 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-99-6 CAPLUS

CN Benzeneacetic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-10-4 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-20-6 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-30-8 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-40-0 CAPLUS

CN Benzoic acid, 4-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-51-3 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-57-9 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-62-6 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-68-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-74-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-79-5 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-90-0 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-00-5 CAPLUS

CN Hexanoic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-06-1 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383659-21-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383659-26-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383659-37-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-42-5 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-(3-phenylpropoxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383659-48-1 CAPLUS


CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(3-phenylpropoxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 2-A



RN 383659-55-0 CAPLUS

CN 1-Naphthalenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-61-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-67-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-73-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-79-8 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-84-5 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-89-0 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-94-7 CAPLUS

CN Acetic acid, [3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-99-2 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-05-7 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-11-5 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-fluorophenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-16-0 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- α,α -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-21-7 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- γ,γ -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-26-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-32-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-38-6 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-43-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-48-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-52-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-57-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-62-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-67-1 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-72-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-77-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-82-0 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-87-5 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-93-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-98-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-propoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-03-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 3-(carboxymethoxy)-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-08-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-12-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-17-4 CAPLUS

CN Benzo[b]thiophene-2-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-22-1 CAPLUS

CN 2-Benzofuranpropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-27-6 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-31-2 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-36-7 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-40-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-45-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,6,7-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-50-5 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-chloro-7-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

DA ANSWER 16 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:932483 CAPLUS

DOCUMENT NUMBER: 136:50294

TITLE: Drug design of squalene synthase inhibitors by X-ray structure computer analysis

INVENTOR(S): Usui, Hiroyuki; Katakura, Shinichi; Suzuki, Makoto

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 131 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001354587	A2	20011225	JP 2000-177413	20000613
PRIORITY APPLN. INFO.: GI			JP 2000-177413	20000613



AB A method for designing inhibitors of squalene synthase by computer anal. of X-ray crystallog. structure of the enzyme complexed with the known inhibitors, is disclosed. Divalent metal ion binding or hydrogen bonding by the carboxyl groups of Asp80, Glu83, and Asp84, or Asp219, Glu222, and Asp223, are used for inhibition. The compds. having the general structure I (Ar = possibly substituted single or double aromatic ring, R1 = single or double ring aromatic heterocycle, possibly substituted with single or double ring aromatic heterocycle, or C2-C6 alkenyl, A1 and A2 = C, O, S, CH, CR2, CH2, CHR3, C=O, NH, or NR4 (R2, R3, and R4 = C1-C6 alkyl)) or II (R1, A1, A2, same as above, B and Y = C, O, S, CH, CR2, CH2, CHR3, C=O, NH, or NR4 (R2, R3, and R4 = C1-C6 alkyl)), as preventive or therapeutic agent for hypercholesterolemia are claimed. Crystals of the complex of the soluble domain of squalene synthase (amino acid residues 31-370) with previously known inhibitors, D-61-7267 (III) (WO 9829380) and D-91-1169 (IV) (JP 09186880) were obtained and the three dimensional structures were determined. Hydrophobic van der Waals interactions between naphthalene rings A and B of III, or benzene ring A of IV, and hydrophobic amino acids, Val179, Leu183, Met207, Gly208, Leu211, Tyr276, Phe288, and Pro292 was detected. Likewise, interactions between naphthalene rings C and D of III, or benzene ring B of IV, and hydrophobic amino acids Phe54, Val69, Phe72, Tyr73, Leu76, Val179, Leu183, and Phe288, were observed.

IT 189058-86-4, D 91-1169


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug design of squalene synthase inhibitors by x-ray structure

10/256,198


computer anal.)
RN 189058-86-4 CAPLUS
CN L-Aspartic acid, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/256,198

LA ANSWER 17 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:900250 CAPLUS
DOCUMENT NUMBER: 136:272650
TITLE: Novel 4,1-benzoxazepine derivatives with potent
squalene synthase inhibitory activities
AUTHOR(S): Miki, Takashi; Kori, Masakuni; Mabuchi, Hiroshi;
Banno, Hiroshi; Tozawa, Ryu-ichi; Nakamura, Masahira;
Itokawa, Shigekazu; Sugiyama, Yasuo; Yukimasa,
Hidefumi
CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical
Industries, Ltd., Yodogawa-ku, Juso-Honmachi, Osaka,
532-8686, Japan
SOURCE: Bioorganic & Medicinal Chemistry (2001), Volume Date
2002, 10(2), 401-414
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:272650
GI



I

AB A series of (3,5-trans)-2-oxo-5-phenyl-1,2,3,5-tetrahydro-4,1-benzoxazepine derivs. were synthesized and evaluated for squalene synthase inhibitory and cholesterol biosynthesis inhibitory activities. Through modification of substituents of the lead compds., it was found that 4,1-benzoxazepine-3-acetic acid derivs. with iso-Bu and neopentyl groups at the 1-position, the chloro atom at the 7-position, and the chloro and methoxy groups at the 2'-position on the 5-Ph ring, had potent squalene synthase inhibitory activity. Among such compds., the 5-(2,3-dimethoxyphenyl) derivative I exhibited potent inhibition of cholesterol biosynthesis in HepG2 cells. As a result of optical resolution study of I, the absolute stereochem. required for inhibitory activity was determined to be 3R,5S. In vivo study showed that the sodium salt of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid effectively reduced plasma cholesterol in marmosets.

IT 152909-46-1P 171868-38-5P 171868-39-6P
171962-07-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine derivs. with potent squalene synthase inhibitory activities)

RN 152909-46-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171868-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 171962-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, sodium salt, (3R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

IT 152909-22-3P 406684-80-8P 406684-81-9P

736155-92-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of benzoxazepine derivs. with potent squalene synthase
inhibitory activities)

RN 152909-22-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 406684-80-8 CAPLUS

CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406684-81-9 CAPLUS

CN L-Leucine, N-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736155-92-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, methyl ester, (3R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 18 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:416879 CAPLUS

DOCUMENT NUMBER: 135:19434

TITLE: Process for production of optically active benzhydrols by asymmetric hydrogenation of benzophenone derivatives

INVENTOR(S): Yamano, Toru; Oi, Satoru; Yamashita, Masayuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040162	A1	20010607	WO 2000-JP8392	20001129
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001220371	A2	20010814	JP 2000-362780	20001129
PRIORITY APPLN. INFO.:			JP 1999-341015	A 19991130
OTHER SOURCE(S):		CASREACT 135:19434; MARPAT 135:19434		
GI				



AB A process for production of optically active compds. of general formula (I) [wherein R1 and R2 are each hydrogen or (un)substituted hydrocarbyl or acyl; ring A or B represents (un)substituted benzene ring; * represents an asym. carbon atom] is characterized by hydrogenating a benzophenone compound of general formula (II; R1 and R2 are same above) in the presence of both an optically active ruthenium-phosphine-amine complex prepared through isolation from a phosphine represented by, e.g., the general formula PR3R4R5 (wherein R3, R4 and R5 are each optionally substituted hydrocarbyl or R3 and R4 are linked together to form a cyclic hydrocarbyl ring), an amine of the general formula NHR8R9 [wherein R8 and R9 are each hydrogen or (un)substituted hydrocarbyl] and a ruthenium complex, and a base. This process efficiently gives optically active benzhydrols, which are useful as intermediates for drugs such as squalene synthetase inhibitors and triglyceride-lowering agents, in high yields under mild conditions at low hydrogen pressure and near room temperature Thus, 292 mg (2-amino-5-chlorophenyl) (2,3-dimethoxyphenyl)methanone and 24 mg [RuCl2[(R)-xylBINAP]][(R)-daipen] [xyl-BINAP = 2,2'-bis(dicyclohexylphosphino)-6,6'-

dimethyl-1,1'-biphenyl, daipen = 1-isopropyl-2,2-bis(p-methoxyphenyl)ethylenediamine] (REG 220114-32-9) were added to a glass autoclave, followed by purging the autoclave with Ar and adding a solution of 0.03 mL 1.0 M Me₃COK/Me₃COH and 2 mL toluene which had been purged with Ar, and the resulting mixture was purged with Ar and stirred at room

temperature

under hydrogen pressure of 7 atm to give 97.1% (S)-(2-amino-5-chlorophenyl)(2,3-dimethoxyphenyl)methanol (98.7% e.e.). The latter compound was converted in 8 steps into N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid which is a known squalene synthetase inhibitor.

IT 189059-61-8P 189059-65-2P 189059-71-0P

189060-51-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(process for production of optically active benzhydrols by asym.

hydrogenation of benzophenone derivs. in presence of optically active ruthenium phosphine amine complex)

RN 189059-61-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, ethyl ester, (3R,5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-51-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT **189060-13-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(process for production of optically active benzhydrols by asym.

hydrogenation of benzophenone derivs. in presence of optically active ruthenium phosphine amine complex)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

~~LA~~ ANSWER 19 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:224390 CAPLUS
DOCUMENT NUMBER: 134:252365
TITLE: Preparation of oxazinobenzoxazepineacetates and
analogs as squalene synthetase inhibitors
INVENTOR(S): Hayward, Cheryl M.; Scully, Douglas A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 44 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6207664	B1	20010327	US 1999-441339	19991116
PRIORITY APPLN. INFO.:			US 1998-109939P	P 19981125
OTHER SOURCE(S):	MARPAT	134:252365		
GI				



AB Title compds. [I; R = (un)substituted Ph or -naphthyl; R1,R2 = H, halo, alkyl, alkoxy, etc.; R3 = CO2H, alkoxycarbonyl, CONH2, etc.; R4 = alk(en)yl, cycloalkylmethyl, Ph, etc.; Z = O, S, CH2; Z1 = O or S] were prepared (no data). Thus, (1R,7S,9R)-I [R = C6H3(OMe)2-2,3, R1 = 5-Me, R2 = H, R3 = CO2H, R4 = CMe3, Z1 = Z2 = O] was prepared starting from 3-tert-butyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazine and 2,3-(MeO)2C6H3CHO.


IT 331634-15-2P 331634-23-2P 331634-31-2P
331634-57-2P 331634-58-3P 331634-77-6P
331634-78-7P 331635-12-2P 331635-14-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazinobenzoxazepineacetates and analogs as squalene synthetase inhibitors)

RN 331634-15-2 CAPLUS

CN 8H-1,4-Oxazino[2,3,4-jk][4,1]benzoxazepine-6-acetic acid,
10-chloro-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-
5-oxo-, (3R,6R,8S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331634-23-2 CAPLUS

CN 1H,6H-Pyrido[3,2,1-jk][4,1]benzoxazepine-3-acetic acid,
10-chloro-1-(2,3-dimethoxyphenyl)-6-(1,1-dimethylethyl)-3,4,7,8-tetrahydro-
4-oxo-, (1R,3S,6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331634-31-2 CAPLUS

CN 1H,6H-Pyrido[3,2,1-jk][4,1]benzoxazepine-3-acetic acid,
10-chloro-1-(2,3-dimethoxyphenyl)-3,4,7,8-tetrahydro-6-(1-methylethyl)-4-
oxo-, (1R,3S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 331634-57-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(1R,3S,6R)-10-chloro-1-(2,3-
dimethoxyphenyl)-6-(1,1-dimethylethyl)-3,4,7,8-tetrahydro-4-oxo-1H,6H-
pyrido[3,2,1-jk][4,1]benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX

10/256,198

NAME)


Relative stereochemistry.



RN 331634-58-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[(1R,3S,6R)-10-chloro-1-(2,3-dimethoxyphenyl)-6-(1,1-dimethylethyl)-3,4,7,8-tetrahydro-4-oxo-1H,6H-pyrido[3,2,1-jk][4,1]benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331634-77-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[(1R,3S,6R)-10-chloro-1-(2,3-dimethoxyphenyl)-3,4,7,8-tetrahydro-6-(1-methylethyl)-4-oxo-1H,6H-pyrido[3,2,1-jk][4,1]benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331634-78-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(1R,3S,6R)-10-chloro-1-(2,3-dimethoxyphenyl)-3,4,7,8-tetrahydro-6-(1-methylethyl)-4-oxo-1H,6H-pyrido[3,2,1-jk][4,1]benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-12-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R,6R,8S)-10-chloro-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-14-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[(3R,6R,8S)-10-chloro-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:180583 CAPLUS

DOCUMENT NUMBER: 128:230397

TITLE: Preparation of 4,1-benzoxazepin-2-one derivatives and their uses

INVENTOR(S): Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki; Sugiyama, Yasuo

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: U.S., 105 pp., Cont.-in-part of U.S. Ser. No. 195,131, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5726306	A	19980310	US 1994-338163	19941109
US 5885979	A	19990323	US 1997-852292	19970507
PRIORITY APPLN. INFO.:			JP 1992-99541	A 19920420
			JP 1992-339947	A 19921221
			US 1993-49455	B1 19930420
			US 1994-195131	B2 19940209
			JP 1994-244136	A 19941007
			US 1994-338163	A3 19941109

OTHER SOURCE(S): MARPAT 128:230397

GI



AB Title compds. I (R = halogen; R1 = H, benzyl, alkyl, alkynyl, etc.; R2 = H, alkyl, Ph, heterocyclic, etc.; R3 = H, alkyl, Ph, heterocyclic, etc.; X = bond, spacer with chain length of 1-7 atoms; Y = carboxyl, alkoxy carbonyl, hydroxyl, amino group, Ph, carbamoyl group, etc.) and salts are prepared from condensation of II with 5-oxo-tetrahydro-2-furancarboxyl chloride and ClCO(Z)nCOOR4 ((Z)n = (CH2)3, CHCl(CH2)2, trans-CH:CH, etc.;

R4 = H, Et, etc.). Title compds. I are useful for inhibiting squalene synthetase and fungal growth, and which are useful for treating or preventing hyperlipidemia in oral tablets or injections.

IT **171868-39-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzoxazepinone derivs. and their uses)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **171868-38-5P 171962-07-5P 204585-86-4P 204586-14-1P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepinone derivs. and their uses)

RN 171868-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 171962-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, sodium salt, (3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● Na


RN 204585-86-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 204586-14-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

IT 171768-62-0P 171768-63-1P 171868-45-4P
171868-46-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepinone derivs. and their uses)

RN 171768-62-0 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-63-1 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 171868-45-4 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-46-5 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:31309 CAPLUS

DOCUMENT NUMBER: 128:102107

TITLE: Preparation of 4,1-benzoxazepines and
4,1-benzothiazepines and their use as squalene
synthetase inhibitors

INVENTOR(S): Hamanaka, Ernest Seiichi; Hayward, Cheryl Myers

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748701	A1	19971224	WO 1997-IB550	19970514
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9724016	A1	19980107	AU 1997-24016	19970514
US 6537987	B1	20030325	US 1998-202106	19981218
PRIORITY APPLN. INFO.:			US 1996-22365P	P 19960620
			WO 1997-IB550	W 19970514
OTHER SOURCE(S):	MARPAT 128:102107			
GI				



AB The invention relates to certain benzoxazepinones and benzothiazepinones I and their pharmaceutically acceptable cationic and anionic salts, prodrugs, and stereoisomers [wherein X = O, S, S(O), or S(O)₂; Y = CO or CH₂; T = 4- to 7-membered mono-aza saturated heterocycle bound at N, optionally containing thio or oxo and optionally monosubstituted on C with OH, Cl-4 alkoxy, or CO₂H; Z = CO₂H or derivs., including tetrazol-5-yl; Z₁ = H, CO₂H, OH, alkoxy, alkoxycarbonyl; R₁, R₂ = H, halo, OH, CF₃, alkyl, fluoroalkyl, alkoxy, Ph, amino, certain heterocyclyl, etc.; R₃ = (un)substituted Ph; R₄ = (un)substituted alkyl, alkenyl, cycloalkylmethyl, or heterocyclylalkyl]. The compds. are useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimer's agents, and anti-acne agents (no data). Examples include over 200 invention compds. For instance, reductive alkylation of 4-ClC₆H₄NH₂ with pivaldehyde and NaBH₄ gave 99% 4-ClC₆H₄NHCH₂CMe₃, which reacted with BCl₃ and then 2,3-ethylenedioxybenzaldehyde and Et₃N to give 88% (5-chloro-2-neopentylaminophenyl)(2,3-ethylenedioxyphenyl)methanol. The latter underwent a sequence of amidation with (E)-ClCOCH:CHCO₂Et (90%), cyclization by treatment with K₂CO₃ in EtOH (67%), alkaline saponification of the ester (91%), and amidation with Et isonipecotate (68%), to give title compound II.


IT 201218-86-2P 201218-89-5P 201218-92-0P
 201218-95-3P 201219-01-4P 201219-06-9P
 201219-13-8P 201219-14-9P 201219-28-5P
 201219-36-5P 201219-37-6P 201219-74-1P
 201219-75-2P 201219-86-5P 201219-87-6P
 201219-89-8P 201219-90-1P 201220-01-1P
 201220-06-6P 201220-07-7P 201220-21-5P
 201220-29-3P 201220-30-6P 201220-71-5P
 201220-72-6P 201419-55-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazepines and benzothiazepines as squalene synthetase inhibitors)

RN 201218-86-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201218-89-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201218-92-0 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201218-95-3 CAPLUS

CN 2,4-Piperidinedicarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dimethyl ester, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-01-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-06-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-5-(2,3,4-trimethoxyphenyl)-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-13-8 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201219-14-9 CAPLUS

CN D-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (4R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201219-28-5 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-36-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-37-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-74-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-75-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-86-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-87-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3α,5β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-89-8 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201219-90-1 CAPLUS

CN 2,4-Piperidinedicarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-01-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-5-(2,3,4-trimethoxyphenyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-06-6 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201220-07-7 CAPLUS

CN D-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201220-21-5 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-29-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-30-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 α ,5 β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-71-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-72-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3α,5β)-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201419-55-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 152909-46-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of benzoxazepines and benzothiazepines as squalene synthetase inhibitors)

RN 152909-46-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



10/256,198

~~LA~~ ANSWER 22 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:365842 CAPLUS
DOCUMENT NUMBER: 127:34256
TITLE: Preparation of fused ring compounds as cholesterol
lowering agents
INVENTOR(S): Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09087260	A2	19970331	JP 1995-249758	19950927
PRIORITY APPLN. INFO.:			JP 1995-249758	19950927
OTHER SOURCE(S):	MARPAT	127:34256		
GI				



AB The title compds. [I; R¹ = H, (un)substituted hydrocarbyl; R² = H, (un)substituted hydrocarbyl, heterocyclyl; X = (un)substituted sulfonic acid, etc.; ring A = (un)substituted benzene ring or heterocycle ring; ring J = 7-8 numbered heterocycle; D = C, N; n = 1-2] are prepared I, possessing cholesterol, lipid, and triglyceride lowering activity, are useful for prevention and treatment of hyperlipemia. Thus, benzoxazepine derivative (II; X = Et) (preparation given) was treated with concentrate HCl in dioxane

to give the title compound II (X = H) (III). III which showed IC₅₀ of 23 and 19 μM against rat and human cholesterol synthase resp. A capsule, tablet, and injectable formulation containing I were also prepared


IT 189681-29-6P 189681-31-0P 189681-33-2P
189681-34-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of fused ring compds. as cholesterol lowering agents)

RN 189681-29-6 CAPLUS

CN Phosphonic acid, [2-[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-, diethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-31-0 CAPLUS

CN Phosphonic acid, [[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, diethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-33-2 CAPLUS

CN 4,1-Benzoxazepine-3-methanesulfonic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, sodium salt, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 189681-34-3 CAPLUS

CN 4,1-Benzoxazepine-3-methanesulfonic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 189681-30-9P 189681-32-1P 189681-35-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of fused ring compds. as cholesterol lowering agents)

RN 189681-30-9 CAPLUS

CN Phosphonic acid, [2-[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-32-1 CAPLUS

CN Phosphonic acid, [[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-35-4 CAPLUS

CN 4,1-Benzoxazepine-3-methanesulfonamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 171868-39-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(Preparation of fused ring compds. as cholesterol lowering agents)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 189681-36-5P 189681-37-6P 189681-38-7P

189681-39-8P 189681-40-1P 189681-41-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation of fused ring compds. as cholesterol lowering agents)

RN 189681-36-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-(2-hydroxyethyl)-, sodium salt, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 189681-37-6 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-[2-[(methylsulfonyl)oxy]ethyl]-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-38-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 3-(aminomethyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-39-8 CAPLUS

CN Thiocyanic acid, [7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl ester, (3S-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-40-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-(hydroxymethyl)-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189681-41-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-[[(methylsulfonyl)oxy]methyl]-, (3R-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



18256,198

44 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:317788 CAPLUS

DOCUMENT NUMBER: 126:293368

TITLE: Benzoxazepine compounds, their production and use as lipid lowering agents

INVENTOR(S): Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710224	A1	19970320	WO 1996-JP2596	19960912
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2231052	AA	19970320	CA 1996-2231052	19960912
AU 9669442	A1	19970401	AU 1996-69442	19960912
JP 09136880	A2	19970527	JP 1996-242378	19960912
JP 3479796	B2	20031215		
EP 862562	A1	19980909	EP 1996-930365	19960912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1196052	A	19981014	CN 1996-196892	19960912
CN 1072649	B	20011010		
JP 2001097963	A2	20010410	JP 2000-323310	19960912
EP 1097928	A1	20010509	EP 2000-126672	19960912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 202774	E	20010715	AT 1996-930365	19960912
ES 2158344	T3	20010901	ES 1996-930365	19960912
PT 862562	T	20011130	PT 1996-930365	19960912
ZA 9702134	A	19990604	ZA 1997-2134	19970312
US 6110909	A	20000829	US 1998-43265	19980312
US 6613761	B1	20030902	US 2000-587947	20000606
GR 3036707	T3	20011231	GR 2001-401564	20010926
US 2004072819	A1	20040415	US 2003-606152	20030624
PRIORITY APPLN. INFO.:			JP 1995-235457	A 19950913
			EP 1996-930365	A3 19960912
			JP 1996-242378	A3 19960912
			WO 1996-JP2596	W 19960912
			ZA 1997-2134	A 19970312
			US 1998-43265	A3 19980312
			US 2000-587947	A1 20000606

OTHER SOURCE(S): MARPAT 126:293368
GI



AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted CONH2, heterocyclic group having a deprotonatable hydrogen atom] were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = CO2H] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of 11X10⁻⁹ M.


IT **189058-78-4P 189059-51-6P 189059-84-5P**
189059-85-6P 189059-92-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-78-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-51-6 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-84-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-92-5. CAPLUS

CN Phosphonic acid, [[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189058-84-2P 189058-85-3P 189058-86-4P
 189058-88-6P 189058-91-1P 189058-94-4P
 189058-95-5P 189058-96-6P 189058-97-7P
 189059-02-7P 189059-05-0P 189059-06-1P
 189059-07-2P 189059-54-9P 189059-55-0P
 189059-72-1P 189059-79-8P 189059-80-1P
 189059-81-2P 189059-82-3P 189059-83-4P
 189059-90-3P 189059-91-4P 189059-93-6P
 189059-96-9P 189059-98-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylbenzoxazepinones as hypolipemic agents)


RN 189058-84-2 CAPLUS

CN D-Isoleucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

10/256,198

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-85-3 CAPLUS

CN L-Glutamic acid, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 5-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-86-4 CAPLUS

CN L-Aspartic acid, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 5-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-88-6 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-91-1 CAPLUS

CN L-Phenylalanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-94-4 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinylidene]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-95-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-96-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-97-7 CAPLUS

CN β -Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-02-7 CAPLUS

CN L-Tyrosine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-05-0 CAPLUS

CN L-Valine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-06-1 CAPLUS

CN L-Leucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-07-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-54-9 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-3-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-55-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, monosodium salt, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 189059-72-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-79-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methylphenyl) sulfonyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-80-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-81-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(1-methylethyl)sulfonyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-82-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-N-(ethylsulfonyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-83-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-90-3 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-91-4 CAPLUS

CN Phosphonic acid, [[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-93-6 CAPLUS

CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-96-9 CAPLUS

CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-[2-(1H-tetrazol-5-yl)ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-98-1 CAPLUS

CN Phosphonic acid, [[[[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 171868-39-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 189058-37-5P 189058-38-6P 189058-39-7P
 189058-40-0P 189058-41-1P 189058-42-2P
 189058-43-3P 189058-44-4P 189058-45-5P
 189058-46-6P 189058-47-7P 189058-48-8P
 189058-49-9P 189058-50-2P 189058-51-3P
 189058-52-4P 189058-53-5P 189058-54-6P
 189058-55-7P 189058-56-8P 189058-57-9P
 189058-58-0P 189058-59-1P 189058-61-5P
 189058-62-6P 189058-63-7P 189058-64-8P
 189058-65-9P 189058-66-0P 189058-67-1P
 189058-68-2P 189058-69-3P 189058-70-6P
 189058-71-7P 189058-72-8P 189058-73-9P
 189058-74-0P 189058-75-1P 189058-76-2P
 189059-10-7P 189059-40-3P 189059-42-5P
 189059-52-7P 189059-53-8P 189059-57-2P
 189059-61-8P 189059-62-9P 189059-63-0P
 189059-64-1P 189059-65-2P 189059-66-3P
 189059-67-4P 189059-68-5P 189059-69-6P
 189059-71-0P 189059-87-8P 189059-88-9P
 189059-89-0P 189059-94-7P 189059-95-8P
 189059-97-0P 189060-00-2P 189060-01-3P
 189060-02-4P 189060-19-3P 189060-21-7P
 189060-24-0P 189060-27-3P 189060-30-8P
 189060-41-1P 189060-51-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-37-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-38-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-39-7 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-40-0 CAPLUS

CN D-Serine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-41-1 CAPLUS

CN D-Threonine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-42-2 CAPLUS

CN L-Proline, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-43-3 CAPLUS

CN L-Proline, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-44-4 CAPLUS

CN D-Isoleucine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-45-5 CAPLUS

CN L-Glutamic acid, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 5-ethyl 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-46-6 CAPLUS

CN L-Aspartic acid, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-47-7 CAPLUS

CN L-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-48-8 CAPLUS

CN Glycine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-49-9 CAPLUS

CN L-Serine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-50-2 CAPLUS

CN L-Asparagine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-51-3 CAPLUS

CN L-Phenylalanine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-52-4 CAPLUS

CN L-Glutamine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-53-5 CAPLUS

CN L-Threonine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-54-6 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinylidene]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-55-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-56-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-57-9 CAPLUS

CN β -Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-58-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester, [3R-[trans(trans)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-59-1 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-61-5 CAPLUS

CN Benzeneacetic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-62-6 CAPLUS

CN L-Tyrosine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-63-7 CAPLUS

CN L-Histidine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-64-8 CAPLUS

CN L-Tryptophan, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-65-9 CAPLUS

CN L-Valine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-66-0 CAPLUS

CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-67-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-2-oxo-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-68-2 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-69-3 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189058-70-6 CAPLUS

CN 2-Butenoic acid, 4-[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]-, ethyl ester, [3R-[3α(E),5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 189058-71-7 CAPLUS

CN 4-Piperidineacetic acid, 4-(acetyloxy)-1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-72-8 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-73-9 CAPLUS

CN Phosphonic acid, [[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]methyl]-, bis(1-methylethyl) ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-74-0 CAPLUS

CN Phosphonic acid, [[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, diethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-75-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-76-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-10-7 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-40-3 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-42-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-53-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetonitrile, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-57-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-61-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, ethyl ester, (3R,5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-62-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-63-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-64-1 CAPLUS

CN 1H-Tetrazole-1-propanenitrile, 5-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-66-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-67-4 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyldene]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-68-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-69-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-87-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-88-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-89-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-94-7 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-95-8 CAPLUS

CN 4-Piperidineacetone nitrile, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-97-0 CAPLUS

CN Phosphonic acid, [[[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, diethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-00-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-01-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-02-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-19-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-21-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-24-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-27-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetonitrile, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-30-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-51-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189058-77-3P 189058-79-5P 189058-80-8P
 189058-81-9P 189058-82-0P 189058-83-1P
 189058-87-5P 189058-89-7P 189058-90-0P
 189058-92-2P 189058-93-3P 189058-98-8P
 189058-99-9P 189059-01-6P 189059-03-8P
 189059-04-9P 189059-08-3P 189059-09-4P
 189059-11-8P 189059-12-9P 189059-13-0P
 189059-14-1P 189059-15-2P 189059-16-3P
 189059-17-4P 189059-18-5P 189059-19-6P
 189059-20-9P 189059-21-0P 189059-22-1P
 189059-23-2P 189059-24-3P 189059-25-4P
 189059-26-5P 189059-27-6P 189059-28-7P
 189059-29-8P 189059-30-1P 189059-31-2P
 189059-32-3P 189059-33-4P 189059-34-5P
 189059-35-6P 189059-36-7P 189059-37-8P
 189059-38-9P 189059-39-0P 189059-41-4P
 189059-43-6P 189059-44-7P 189059-45-8P
 189059-46-9P 189059-47-0P 189059-48-1P
 189059-49-2P 189059-50-5P 189059-56-1P
 189059-70-9P 189059-73-2P 189059-74-3P
 189059-75-4P 189059-76-5P 189059-77-6P
 189059-78-7P 189059-99-2P 189060-04-6P
 189060-05-7P 189060-07-9P 189060-10-4P
 189060-13-7P 189060-16-0P 189060-33-1P
 189060-37-5P 189060-45-5P 189060-48-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-77-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-79-5 CAPLUS

CN Glycine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-80-8 CAPLUS

CN D-Serine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-81-9 CAPLUS

CN D-Threonine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-82-0 CAPLUS

CN L-Proline, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-83-1 CAPLUS

CN L-Proline, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-87-5 CAPLUS

CN L-Methionine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-89-7 CAPLUS

CN L-Serine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-90-0 CAPLUS

CN L-Asparagine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-92-2 CAPLUS

CN L-Glutamine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-93-3 CAPLUS

CN L-Threonine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-98-8 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, [3R-[trans(trans)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-99-9 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-01-6 CAPLUS

CN Benzeneacetic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-03-8 CAPLUS

CN L-Histidine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-04-9 CAPLUS

CN L-Tryptophan, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-08-3 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-09-4 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-11-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 189059-12-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-(4-morpholinyl)ethyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-13-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-piperidinyl)ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-14-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-piperidinyl)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-15-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 189059-16-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-17-4 CAPLUS

CN 4-Piperidinamine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N,N-dimethyl-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(3,4-dihydro-2(1H)-isoquinoliny)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-20-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(4-morpholinyl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-21-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-pyrrolidinyl)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-22-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-23-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-24-3 CAPLUS

CN 4-Piperidinol, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189059-25-4 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, [3R-[3α(R*),5β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-26-5 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, [3R-[3 α (S*),5 β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-27-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-3-methylbutyl]-2-oxo-, [3R-[3 α (R*),5 β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-28-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-3-methylbutyl]-2-oxo-, [3R-[3 α (S*),5 β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-29-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(2-hydroxy-1-phenylethyl)-2-oxo-, [3R-[3 α (R*),5 β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-30-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-2-methylpropyl]-2-oxo-, [3R-[3α(S*),5β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-31-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-32-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(3-hydroxypropyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-33-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(2-hydroxyethyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-34-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-2-phenylethyl]-2-oxo-, [3R-[3α(S*),5β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-35-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(2-hydroxy-1-methylethyl)-2-oxo-, [3R-[3α(R*),5β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-36-7 CAPLUS

CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4,4-dimethoxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-37-8 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-38-9 CAPLUS

CN 4-Piperidinone, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-39-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-41-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-43-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-methyl-6-(1-methylethyl)phenyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-44-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-(2,4-difluorophenyl)-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-45-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-2-propenyl-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-46-9 CAPLUS

CN Morpholine, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189059-47-0 CAPLUS

CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189059-48-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N,N-dimethyl-2-oxo-, (3R-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189059-49-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-50-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-1H-tetrazol-5-yl-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-56-1 CAPLUS

CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-(1H-tetrazol-5-yl)-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-73-2 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinylidene]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-74-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-75-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-76-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-77-6 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-78-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-99-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]methyl]phosphinylidene]bis(oxymethylene) ester, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 189060-05-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-07-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-16-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-33-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-45-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-48-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/256,198

L4 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:457956 CAPLUS
DOCUMENT NUMBER: 125:123701
TITLE: Antihypertriglyceridemic composition
INVENTOR(S): Sugiyama, Yasuo; Yukimasa, Hidefumi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Can. Pat. Appl., 59 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2160092	AA	19960408	CA 1995-2160092	19951006
PRIORITY APPLN. INFO.:			JP 1994-94	U 19941007

OTHER SOURCE(S): MARPAT 125:123701

GI For diagram(s), see printed CA Issue.

AB An antihypertriglyceridemic composition comprises a compound I (R1 = H, hydrocarbon group; R2, R3 = H, hydrocarbon group, heterocyclic group; X = carboxyl group, carbamoyl group, OH, amino group, heterocyclic group; A = benzene ring, heterocyclic ring; J = 7- or 8-membered heterocyclic ring) or a pharmacol. acceptable salt thereof. The composition has a plasma triglyceride concentration-lowering activity, and therefore is useful for the prophylaxis or treatment of hypolipemia, such as hypertriglyceridemia. Examples for formulating capsules, tablets, and injections containing I are given.

IT 171868-39-6 171962-07-5 179124-62-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hypolipemic compns. containing fused-cyclic compds.)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 171962-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

10/256,198

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, sodium salt, (3R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● Na

RN 179124-62-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



14 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:342064 CAPLUS
 DOCUMENT NUMBER: 125:32076
 TITLE: Production of optically active compounds
 INVENTOR(S): Nakahama, Kazuo; Izawa, Motowo; Nagano, Yoichi; Tarui, Naoki; Matsumoto, Kiyoharu; Kori, Masakuni; Kanamaru, Tsuneo; Nagata, Toshiaki
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 54 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 710725	A1	19960508	EP 1995-117120	19951031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08205889	A2	19960813	JP 1995-281162	19951030
CA 2161849	AA	19960502	CA 1995-2161849	19951031
US 5770438	A	19980623	US 1995-550643	19951031
JP 08298995	A2	19961119	JP 1996-47356	19960305
PRIORITY APPLN. INFO.:			JP 1994-269056	A 19941101
			JP 1995-47156	A 19950307
			EP 1995-117120	A 19951031

OTHER SOURCE(S): MARPAT 125:32076

GI For diagram(s), see printed CA Issue.

AB A process is claimed for producing optically active compds. of formula (I) that have plasma cholesterol- and triglyceride-lowering activities, wherein R1 represents H or a hydrocarbon group that may be substituted; R2 and R3 independently represent H, a hydrocarbon group that may be substituted, or a heteroarom. group that may be substituted; X1 represents a substituent comprising an esterified carboxyl group or an acylated OH group; ring A represents a benzene ring that may be substituted or a heteroarom. ring that may be substituted; ring J1 represents a 7- or 8-membered heterocyclic ring containing ≤3 hetero atoms, which may have a further substituent or substituents in addition to R1, R2, R3, and X1, and C1 denotes a chiral C atom or a salt thereof. The process comprises subjecting the racemic compound of the formula I or a salt thereof, or alternatively a racemic starting compound for synthesizing the compound of the formula I to enzymically enantioselective hydrolysis to provide an optically active form thereof.


IT **177567-40-7P**

RL: BPN (Biosynthetic preparation); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (optically active hypolipemic heterocyclic compound production involving biol. resolution)

RN 177567-40-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



IT **152909-22-3P**


RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(optically active hypolipemic heterocyclic compound production involving biol. resolution of)

RN 152909-22-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



14 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:298262 CAPLUS

DOCUMENT NUMBER: 125:19089

TITLE: Pharmaceutical compositions containing condensed seven- or eight-membered heterocyclic compounds useful as antihypertriglyceridemic agents

INVENTOR(S): Sugiyama, Yasuo; Yukimasa, Hidefumi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 705607	A2	19960410	EP 1995-115109	19950926
EP 705607	A3	19960508		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
TW 401301	B	20000811	TW 1995-84109892	19950921
JP 08157369	A2	19960618	JP 1995-256283	19951003
NO 9503961	A	19960409	NO 1995-3961	19951005
NO 308580	B1	20001002		
AU 9533081	A1	19960418	AU 1995-33081	19951005
AU 703422	B2	19990325		
HU 73422	A2	19960729	HU 1995-2918	19951005
FI 9504773	A	19960408	FI 1995-4773	19951006
CN 1128657	A	19960814	CN 1995-117761	19951006
RU 2166320	C2	20010510	RU 1995-117068	19951006
PRIORITY APPLN. INFO.:			JP 1994-244136	A 19941007

OTHER SOURCE(S): MARPAT 125:19089

GI For diagram(s), see printed CA Issue.

AB An antihypertriglyceridemic composition comprises condensed seven- or eight-membered heterocyclic compds. (I; R1 = H, hydrocarbyl; R2, R3 = H, hydrocarbyl, X' = a carboxyl that may be esterified, a carbamoyl that may be substituted, a hydroxyl that may be substituted, an amino that may be substituted, or an optionally substituted heterocyclic group having a hydrogen atom that may be deprotonated; ring A = represents a benzene ring that may be substituted or a heterocyclic ring that may be substituted; ring J' = a 7- or 8-membered heterocyclic ring having at most 3 hetero-atoms as ring constituent members; and ring J' may have a further substituent in addition to R1, R2 and X'), or a pharmacol. acceptable salt thereof. The composition has a plasma triglyceride concentration-lowering activity, and therefore is useful for the prophylaxis or treatment of hyperlipemia, such as hypertriglyceridemia. A solution of sodium (3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-,1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetate (II) in 0.5% methylcellulose was administered at 30 mg/kg/day to rats for 2 wk under non-fasted condition. The total plasma cholesterol was decreased from 186 to 160 mg/dL and the triglycerides decreased from 353 to 230 mg/dL. A capsule contained II 10, lactose 90, microcryst. cellulose 70, and magnesium stearate 10 mg.

IT 171868-39-6 171962-07-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pharmaceutical compns. containing condensed seven- or eight-membered

heterocyclic compds. useful as antihypertriglyceridemic agents)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 171962-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, sodium salt, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

L4 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:994196 CAPLUS

DOCUMENT NUMBER: 124:55994

TITLE: Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

INVENTOR(S): Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9521834	A1	19950817	WO 1995-JP148	19950206
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2170732	C2	20010720	RU 1999-118298	19930419
AU 9515898	A1	19950829	AU 1995-15898	19950206
JP 07267939	A2	19951017	JP 1995-18972	19950207
BR 9501469	A	19970819	BR 1995-1469	19950406
PRIORITY APPLN. INFO.:			JP 1994-15531	A 19940209
			WO 1995-JP148	A 19950206

OTHER SOURCE(S): MARPAT 124:55994
GI

AB Optically active 4,1-benzoxazepin-2-one derivs. I with (3R-trans)-configuration are disclosed [wherein R1 = alkyl; X = H or metal ion; ring A is substituted with halo; ring B is substituted with alkoxy]. I are useful for the prophylaxis or treatment of hypercholesteremia or coronary sclerosis in mammals. For example racemic trans-II was amidated with H-Ala-OBu-tert.HCl, and the resultant diastereomeric amides were separated by chromatog., deprotected, and hydrolyzed in acid and base, to give

both the desired isomer (3R,5S)-II (A) and its enantiomer (3S,5R)-II (B). In an assay for inhibition of human hepatic squalene synthase in vitro, isomer A had IC₅₀ of 0.011 μ M, vs. 0.020 μ M for its 2-chlorophenyl analog [known from EP 567026]. In a rat enzyme system, the IC₅₀ of isomer A was 0.026 μ M, whereas isomer B only gave 43% inhibition at 10⁻⁵ M.


IT **171868-39-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(desired stereoisomer; preparation of optically active 4,1-benzoxazepine derivs. as squalene synthase inhibitors)

RN 171868-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT **171962-07-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(desired stereoisomer; preparation of optically active 4,1-benzoxazepine derivs. as squalene synthase inhibitors)

RN 171962-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, sodium salt, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

IT 171768-62-0P 171768-63-1P 171868-45-4P
171868-46-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation of optically active 4,1-benzoxazepine derivs. as
squalene synthase inhibitors)

RN 171768-62-0 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-
1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl
ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




p. 19 #1

RN 171768-63-1 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-
1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




p.19 #3

RN 171868-45-4 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




p.19 #2

RN 171868-46-5 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

p. 19
#4


IT 171868-38-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BYP (Byproduct); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(low-activity stereoisomer; preparation of optically active 4,1-benzoxazepine derivs. as squalene synthase inhibitors)

RN 171868-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 152909-46-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of optically active 4,1-benzoxazepine derivs. as squalene synthase inhibitors)

RN 152909-46-1 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



~~L4~~ ANSWER 28 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
 X ACCESSION NUMBER: 1994:164246 CAPLUS
 X DOCUMENT NUMBER: 120:164246
 TITLE: 4,1-Benzoxazepines as squalene synthase inhibitors and
 their use in the treatment of hypercholesteremia and
 as fungicides
 INVENTOR(S): Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni;
 Kitano, Kazuaki
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 194 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 567026	A1	19931027	EP 1993-106276	19930417
EP 567026	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
SG 82630	A1	20010821	SG 1999-3981	19930417
AT 235474	E	20030415	AT 1993-106276	19930417
AU 9337003	A1	19931021	AU 1993-37003	19930419
AU 659543	B2	19950518		
CA 2094335	AA	19931021	CA 1993-2094335	19930419
CA 2094335	C	19931021		
NO 9301433	A	19931021	NO 1993-1433	19930419
NO 304520	B1	19990104		
RU 2145603	C1	20000220	RU 1993-5332	19930419
CN 1083481	A	19940309	CN 1993-106358	19930420
CN 1044237	B	19990721		
JP 06239843	A2	19940830	JP 1993-117857	19930420
JP 3283628	B2	20020520		
HU 71482	A2	19951128	HU 1993-1164	19930420
PRIORITY APPLN. INFO.:			JP 1992-99541	A 19920420
			JP 1992-339947	A 19921221
OTHER SOURCE(S):	MARPAT 120:164246			
GI				



AB The titled compds. I [R1 = H, (un)substituted hydrocarbon group; R2, R3 = H, (un)substituted lower alkyl, (un)substituted Ph or aromatic heterocyclic group; X = direct bond, Z1-7 bridging group; Y = optionally esterified or thioesterified carboxyl group, (un)substituted OH, (un)substituted NH2, (un)substituted Ph, (un)substituted carbamoyl, etc.; ring A may be optionally substituted], which demonstrate inhibition of pathogenic fungal

growth and inhibition of the enzyme squalene synthetase, are prepared and I-containing formulations presented. Thus, the Et ester of N-[(3-R,5-S)-7-chloro-5-(2-chlorophenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]aminocetate was hydrolyzed in NaOH solution, producing N-[(3R,5S)-7-chloro-5-(2-chlorophenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]aminoacetic acid (II). II demonstrated 50% inhibitory concentration against human squalene synthetase of 0.06×10^{-7} M.

IT **152909-22-3P 152909-46-1P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and squalene synthase inhibitory activity and fungicidal activity of)

RN 152909-22-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



RN 152909-46-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

